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ABSTRACT 
BACKGROUND; Endometriosis is a chronic inflammatory disease of unknown origin that 
can cause severe dysmenorrhea, chronic pain and impaired quality of life. Lignocaine has anti-
inflammatory properties and pertubation with lignocaine could be beneficial in the treatment of 
endometriosis-associated pain. The Endometriosis Health Profile-30 (EHP-30) questionnaire is 
specific for endometriosis and evaluates quality of life. One scale on the EHP-30 core 
questionnaire has earlier failed to demonstrate any responsiveness. 
OBJECTIVE; The objectives of the included studies were to evaluate the effect of pertubation 
with Ringer-Lignocaine on dysmenorrhea and quality of life in women with endometriosis. The 
safety and the pharmacokinetics of lignocaine after pertubation were to be investigated. 
Another objective was to evaluate the responsiveness of the EHP-30 questionnaire in a Swedish 
sample. In the final study, the objective was to evaluate the effect of lignocaine on cytokine 
expression and secretion in vitro in peritoneal fluid macrophages and endometriotic stromal 
cells.   
DESIGN; Study I and III were double-blinded, randomised and controlled trials. Study II and 
IV were prospective observational studies and the fifth study was an experimental in vitro study 
on human cells. 
SETTING; The studies were performed at three gynaecological outpatient units in Stockholm, 
Sweden and at the research laboratory at Uppsala Akademiska Hospital, Sweden. 
POPULATION; Eligible patients had endometriosis as diagnosed by laparoscopy, 
dysmenorrhoic pain > VAS 50 mm (visual analogue scale) and patent Fallopian tubes. 42 
women were included in study I, III and IV and of these, 25 were also included in study II. 
Peritoneal fluid and samples from endometriotic cysts were collected from 15 women (patients 
with endometriosis n=9, and healthy controls n=6) during surgery for clinical reasons in study 
V.  
METHODS; The participants in study I-IV were randomised sequentially to pre-ovulatory 
pertubations with placebo (n=18) or lignocaine 1.0 mg/ml (n=24) during three consecutive 
menstrual cycles. The pertubation procedure comprised passing study solution through the 
uterine cavity and the Fallopian tubes via an intracervical placed balloon catheter.  
In study I, the effect on pain was evaluated using a VAS scale before and after the treatments 
and up to nine menstrual cycles after the last pertubation. Success was defined as a reduction of 
pain ≥ 50% on the VAS scale. Fisher’s exact test was used to compare the success rates 
between the treatment and the placebo groups.  
In study II, serum samples were collected at 0, 5, 15 and 30 minutes after pertubation. The 
serum samples were analysed for the concentration of lignocaine with a LCMS-SIM method.  
The effect on quality of life was evaluated with the EHP-30 questionnaire before and after the 
treatments in study III. The changes in scores from baseline to follow-up at six and twelve 
months were compared between the lignocaine and placebo groups with Mann Whitney U test.  
In study IV, the changes on the EHP-30 questionnaire after three pertubations were compared 
with the patients’ self-estimated change in pain intensity. The responsiveness to change for the 
EHP-30 questionnaire was evaluated with effect sizes and significance of change (paired t-test). 
The change in scores between those who improved (improved group) and those who did not 
improve (stable group) were compared with independent t-test.  
In study V, macrophages from the peritoneal fluid and cells from the inside of the endometriotic 
cysts capsules were isolated and cultivated for 24 h-48 h in medium with and without the 
supplement of lignocaine to a final concentration of 0.1 mg/ml or 1.0 mg/ml. Relative gene 
expression of MCP-1, IL-6 and IL-8 were evaluated with RT-PCR and compared between 
treated and untreated cells with Wilcoxon matched pairs. The concentration of MCP-1, IL-6 
  
and IL-8 in cell culture media was measured using ELISA and were compared between treated 
and untreated cells with Wilcoxon matched pairs.  
RESULTS; Study I;  In the Intention To Treat analysis in study I, the success rate was 41.7 % 
(10 of 24) in the treatment group compared to 16.7 % (3 of 18) in the placebo group (p=0.10). 
In the Per Protocol analysis, the proportion of subjects with success in the treatment group was 
45 % (9 of 20) compared to 7.1 % (1 of 14) in the placebo group (p=0.024). Of the nine patients 
in the lignocaine group that fulfilled the criteria for success after three pertubations, four had an 
effect persisting after nine months.  
Study II; Low levels of lignocaine were detected in the serum samples following pertubation of 
10 mg lignocaine hydrochloride. The highest observed concentration was seen after 30 minutes 
with a mean of 0.050 µg/ml and an individual maximum of 0.124 µg/ml.  
Study III; After six months there was a significant difference between the lignocaine (n=19) and 
the placebo (n=16) groups on the dimension social support (median -18.8 vs. -6.3, p=0.034) 
whereas there were no differences for the other dimensions after six or twelve months.  
Study IV; The change in scores were significant for all dimensions (p=0.04-0.0002) except 
sexual intercourse (p=0.29) for improved patients in contrast to the patients in the stable group 
where there were no significant changes in any dimension (p=0.16-0.63). The effect sizes were 
large (>0.8) on all core scales except self image (0.51) for the improved patients and small on 
all scales in the stable group (-0.17-0.35). There were significant differences between the 
improved and the stable group considering change in most of the core EHP-30 scores. 
Study V;  The gene expression and protein secretion of IL-8 in endometriotic stromal cells after 
incubation with lignocaine 0.1 mg/ml was significantly decreased after 24 h compared to 
control (p=0.03 and p=0.02). Macrophages from healthy controls had a significantly lower gene 
expression of all tested cytokines (p=0.04) after treatment with lignocaine but there were no 
significant differences on protein level. Macrophages from patients with endometriosis (n=5) 
showed diverging results since three samples showed increased gene expression of one or two 
cytokines after lignocaine treatment. 
CONCLUSIONS; The first study indicates that pertubation with lignocaine is an efficient, 
non-hormonal treatment option for some patients with dysmenorrhea and endometriosis. The 
serum levels of lignocaine following pertubation of 10 mg lignocaine hydrochloride are 
detectable but low. Pertubation with lignocaine is safe and have no adverse events related to 
lignocaine. Study III indicates that pertubations with lignocaine might improve the social 
support dimension of quality of life in patients with endometriosis. EHP-30 is responsive to 
improvement on all scales on the core questionnaire and is acceptable, understandable and 
applicable in our Swedish sample. Lignocaine can affect the gene expression and secretion of 
the pro inflammatory cytokine IL-8 in vitro. Macrophages from patients with endometriosis 
might be dysregulated. The data presented in this thesis indicate that due to differences at 
cellular level, nearly half of the endometriosis population may benefit from lignocaine 
pertubations. 
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1 INTRODUCTION 
Von Rokitansky first described endometriosis in 1860. There are 176 million women 
suffering from endometriosis worldwide, an invisible disease causing considerable distress 
for affected women and high costs for society (1). Endometriosis is a complex disease and a 
lot of research has been conducted aiming to understand the pathophysiology and thereby 
find effective treatment options. No cure is presently available for this chronic disease and 
previous therapies aiming to relieve the symptoms have clear deficiencies (2). The studies 
presented in this thesis aim to investigate a potential new treatment for patients with 
endometriosis-associated pain.  
 
1.1 BACKGROUND ENDOMETRIOSIS 
 
1.1.1 Definition 
Endometriosis is defined by the presence of endometrium-like tissue with glands and stroma 
located at aberrant locations outside the uterine cavity. The ectopic endometrium is 
implanted over the visceral and peritoneal surfaces in the lower pelvis but also deeper 
locations of endometriotic tissue in the ovaries (endometriotic ovarian cysts) are common. In 
addition, endometriotic implants can infiltrate the rectovaginal septum (adenomyosis 
externa) and the myometrium (adenomyosis interna). Extensive intrapelvic adhesions may 
occur, especially in cases of ovarian endometriosis. Adhesions, fibrosis and scarring around 
endometriotic implants and cysts may distort the anatomy and occlude the fallopian tubes 
(3). Endometriotic lesions can even appear at extra genital locations with the intestinal tract 
being the most common site, constituting 5% of all endometriosis. Other locations in which 
endometriosis can occur is the urinary tract, in scars in the abdominal wall, in the inguinal 
canal and in the thorax (4). 
 
1.1.2 Prevalence and diagnosis 
Endometriosis affects 6-10% of all fertile women and up to 35-50% of females with 
dysmenorrhea and/or infertility, which are the main symptoms of endometriosis (5-8). At 
menopause, the lesions usually disappear and the pain vanishes. 
Laparoscopy or laparotomy with visualisation of endometriotic implants or cysts can confirm 
the diagnosis (8, 9). Operative visualisation of characteristic lesions is generally considered 
an acceptable surrogate for excision with histologic diagnosis of endometriosis (10). The 
lesions can be opaque and nearly invisible, red, brown or white (10, 11). The red lesions 
seem to be the most active form (11). Follow up of women with pelvic pain and 
endometriosis has shown that 17-29 % of lesions resolve spontaneously, 24-64 % progress 
and 9-59 % are stable over a 12 month period (8). The revised scoring system of the 
American Society of Reproductive Medicine (ASRM) is used to determine the disease stage. 
The score is ranging from I, indicating minimal disease, to IV, indicating severe disease 
taking into account the presence and size of ovarian endometriotic cysts and extent, type, and 
site of peritoneal lesions. 
The diagnosis is often delayed and the mean interval between the onset of pain and diagnosis 
is 10.4 years (8, 12). After years of pain women feel relieved when a diagnosis has been 
confirmed (12). Transvaginal ultrasonography and magnetic resonance imaging (MRI) can 
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reliably detect extragenital endometriosis and endometriotic cysts (8, 9) but is unreliable in 
the diagnosis of peritoneal non-ovarian endometriosis (13).  
Efforts have been made to find a non-invasive diagnostic tool to detect peritoneal 
endometriosis. CA-125 may be elevated in serum in patients with endometriosis, but has 
poor sensitivity and specificity and is not recommended for diagnostic purposes (8). Also 
auto-endometrial antibodies and integrin-proteins have been proposed as biomarkers for non-
surgical diagnosis of endometriosis but have failed to prove valuable (11). 
Endometrial biopsy and immunohistochemical nerve fibre detection might be a new and less 
invasive diagnostic test. Women with endometriosis and pelvic pain have fine, non-
myelinated nerve fibres present in the functional layer of the endometrium (14) and the 
density of small nerve fibres is 14 times higher in endometrium from patients with 
endometriosis compared to healthy controls (15).  
 
1.1.3 Symptoms 
Pain in the lower abdomen and subfertility/infertility are the main symptoms of 
endometriosis.  The first symptom is most often dysmenorrhea. Other symptoms that may 
occur over time is non-menstrual pelvic pain, deep dyspareunia, dyschezia, chronic pelvic 
pain and impaired fertility (16). The pain can occur intermittently throughout the menstrual 
cycle or be continuous. Furthermore, the pain can be dull, throbbing or sharp and the pelvic 
pain is usually chronic (lasting > 6 months) (8). The degree of pain is not related to the 
severity as classified by ASRM (8, 17, 18). Neither is there a correlation between pain 
severity and endometriotic ovarian cysts (18).  
Women with endometriosis have a higher incidence of depression and anxiety compared to 
women without endometriosis, and the severity is related to the pain intensity (19-22). 
Depression has proved to be a consequence of the present chronic pain but predisposition to 
depression may increase the likelihood (22). 
Endometriosis patients have impaired health related quality of life (HRQL) compared to 
women without endometriosis (19, 23, 24) and even worse than women with depression 
(25). As with depression, the impairment is related to the degree of pain (19, 26) and women 
with chronic pelvic pain report worse HRQL compared to healthy women (24). Moreover, 
the decreased fertility can affect quality of life since infertile women have lower HRQL 
scores compared to both infertile men and normative data (27). As chronic pelvic pain and 
infertility are the most severe symptoms and consequences of endometriosis, they have the 
highest impact on HRQL in endometriosis patients (2). 
Among women with endometriosis, 30-50% is infertile (3, 11, 28). Infertility is defined as 
the inability to conceive after one year of unprotected intercourse (11) and 25-40% of 
women with infertility have endometriosis (11, 16). In normal couples the probability of 
achieving a pregnancy in any single month is 15-20% whereas it in couples with an untreated 
women with endometriosis is less than 5% and depends on the severity of the disease (11). 
 
1.1.4 Pathogenesis  
The understanding of the pathogenesis and the pathophysiology of the disease remains 
unclear (29). Three theories have been proposed to explain the mechanism behind the 
development of endometriosis (30).  
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The implantation theory (Sampson 1927) includes implantation and growth of endometrium 
following retrograde menstrual reflux. The other two theories suggest that the endometrial 
tissue originate from the peritoneal serosa or from derivates of the Müllerian ducts. The 
theory of coelomic metaplasia (Meyer 1919) proposes that the germinal epithelia of the 
ovary could be transformed by metaplasia into endometrium (30).  
 
There are convincing evidence supporting all theories but the reflux implantation theory is 
the most widely accepted. The anatomical distribution of implants follows the distribution of 
menstrual reflux. The endometrium fragments reaching the peritoneal cavity are viable and 
can attach to the peritoneum. They can degrade the basal membrane, produce angiogenic 
factors essential for neovascularisation and thereby implant in the peritoneal surfaces (30, 
31).  
The reflux of menstrual debris seems to be necessary but not sufficient for the development 
of endometriosis. Retrograde menstruation can be seen as a physiologic phenomenon in 76-
90% of all women (29, 32, 33) but only around 10% develop endometriosis. In most women 
the peritoneal environment is capable of resorbing the menstrual debris from the peritoneal 
cavity at the end of menstruation, preventing it to adhere to the peritoneal surfaces. In 
patients developing endometriosis the cleaning system seems to be insufficient. 
Immunologic changes, genetic factors and environmental factors may determine the 
susceptibility to develop endometriosis (34). A composite theory of retrograde menstruation 
with implantation of endometrial fragments in conjunction with immunological and 
peritoneal factors is the most widely accepted explanation for endometriosis (28, 34, 35).  
 
It has been proposed that the mechanism behind the development of ovarian endometriosis 
and deep endometriosis is different from the development of superficial implants (5, 26, 36). 
It has been suggested that superficial endometriotic implants located on the ovarian surfaces 
could be invaginated or a functional ovarian cyst could be secondary involved by 
endometrial implants on the peritoneal surface (5). In addition, the mesothelium covering the 
ovary could invaginate and undergo coelomic metaplasia and subsequent formation of 
endometriotic cysts (5, 36).  Deep endometriotic lesions in the rectovaginal septum might be 
an evolution of peritoneal endometriosis of the pouch of Douglas secondary to infiltration 
(5). The fact that 93.5% of cases with deep endometriosis also have superficial implants, 
endometriotic ovarian cysts and/or pelvic adhesions, support this theory (5). 
 
Thus, epidemiological, surgical and pathological data consistently suggest that peritoneal, 
ovarian and deep lesions constitute different expressions of one single disease with a unique 
pathogenic mechanism i.e. retrograde menstruation (5). Hereditary factors, immunological 
environment and local hormone concentrations in peritoneal fluid or ovary will determine 
whether the endometrial implants will develop into typical lesions, deep endometriosis or 
cystic ovarian endometriosis (30, 31). High concentrations of oestradiol are needed for the 
development of endometriotic cysts and are found only inside or in the proximity of the 
ovary (30, 31). Superficial endometrial implants are regulated by peritoneal fluid factors, 
deep endometriosis is affected by blood factors and cystic ovarian endometriosis by ovarian 
factors (31).  
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1.1.5 Risk factors 
Endometriosis may occur if the amount of tissue is too great or if the capacity of the intra-
abdominal cells to clear the abdominal cavity is impaired. Excessive menstruation or an 
obstructive uterine anomaly, which increases the menstrual reflux, increases the risk for 
endometriosis (5, 28, 37-39). Women with early menarche, late menopause and nulliparous 
have an increased risk (5) whereas prolonged lactation and multiple pregnancies are 
protective (8). The risk also seems to be higher with increasing age (5).  
The genetic factor in the aetiology of endometriosis is strong (5, 30, 31) and the risk of 
endometriosis is seven-fold increased in women with first degree relatives having 
endometriosis (40). Endometriosis is associated with higher risks of autoimmune diseases 
and ovarian endometrioid and clear-cell cancers, as well as other cancers, including non-
Hodgkin’s lymphoma and melanoma (8). 
Various exposure factors, for example dioxin, are thought to be associated to endometriosis 
by stimulating the production of pro-inflammatory cytokines (41). 
 
 
1.1.6 Pathophysiology 
The endometrium, the immune system, the peritoneum and the fallopian tubes are all 
suggested factors to be involved in the pathophysiology of endometriosis.  
 
1.1.6.1 Endometrium 
The eutopic endometrium differs between women with and without endometriosis and has a 
higher capacity to implant and grow on peritoneal surfaces (30). Factors favouring the 
implantation of the endometrium have been identified for all processes potentially involved 
in the phenomenon. Molecules involved in apoptosis and adhesion, growth and angiogenic 
factors, matrix metalloproteinases and mechanisms involved in the escape from the immune 
system have all been recognized as qualitatively or quantitatively different in eutopic and/or 
ectopic endometrium of women with endometriosis compared to the endometrium of 
disease-free women. These alterations might affect the physiological activity of 
endometrium and are thought to explain why only some women develop the disease (5). 
Molecular alterations between the endometriotic lesions and the eutopic endometrium in 
women with endometriosis have been found. These can be constitutive and/or acquired since 
the pathological peritoneal and ovarian environment in women with endometriosis might 
modify a normal endometrium (5, 31).  
Other abnormalities found in endometriotic implants and in eutopic endometrium of 
endometriotic patients include abnormal expression of aromatase and a progesterone 
resistance (6).  
1.1.6.2 Immunological changes 
There is substantial evidence that immunological factors play a decisive role in the 
development and pathogenesis of endometriosis (38, 42). Observed immune alterations 
include increased number and activation of peritoneal macrophages, decreased T-cells 
reactivity and NK cell cytotoxicity, increased autoantibodies and changes in the cytokine 
network (29). Immunological changes may determine the ability of endometrial implants to 
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survive in ectopic locations and thereby the susceptibility of a woman to endometriosis (29, 
32). Whether the anomalies may contribute to the development of endometriosis or are a 
consequence of the disease has not been resolved (28-30, 33).  
It is agreed that a local sterile and chronic inflammation occurs in the peritoneal cavity in 
patients with endometriosis (42). Macrophages appear to play a leading role in the process 
but other cell types contributing to the inflammatory process are peritoneal mesothelium, 
lymphocytes and the endometrium itself. A complicated network of different cell types and 
their secretory products interact locally and can regulate cell proliferation, activation, 
motility, adhesion, chemotaxis and morphogenesis in many different cell types (28, 38, 43). 
The peritoneal inflammation can in this way affect the implantation, growth, invasiveness, 
neovascularisation and maintenance of the endometrial implants and may also give rise to 
symptoms such as pain, infertility and adhesions (28, 30).  
Elevated serum levels of CRP and CA-125 indicate a generalized inflammatory activity that 
in some patients give symptoms such as fever and a general feeling of malaise, especially 
during periods with more pain (44). 
 
1.1.6.2.1 The role of the peritoneal fluid 
The peritoneal fluid (PF) in women with endometriosis contains increased amount of 
immunologic cells and inflammatory mediators such as cytokines, prostaglandins and growth 
factors (28, 41, 45). The cellular constituents include macrophages, NK cells, lymphocytes, 
eosinophils, mesothelial cells and mast cells. The PF also contains steroid hormones, 
prostaglandins, cytokines and growth factors (28, 42). It arises primarily from plasma 
transudate and ovarian exudate but other sources are tubal fluid, retrograde menstruation and 
macrophage secretions (28).  The volume of PF is usually around 5-20 ml but varies widely 
during the menstrual cycle and between individuals (28, 31). The volume of PF in women 
with endometriosis might be modestly increased (28, 42).  
The PF is a specific microenvironment and the concentration of soluble constituents around 
endometriotic implants might be higher especially if accompanied by adhesions, due to 
compartmentalization (31). Ovarian steroid hormone concentrations are 10-100 fold higher 
in PF than in plasma (31). The PF surrounding the endometriotic implant is dynamic (42) 
and have a large exchange area with plasma through peritoneum (31). 
 
1.1.6.2.2 Cell-mediated immunity and endometriosis 
Macrophages constitute 85% of the cells in the peritoneal fluid (42, 45) and probably 
represent the first line host response to an inflammatory stimulus (28). Macrophages digest 
and process peritoneal debris such as spermatozoa and endometrial tissue and present 
antigens to T-cells. In addition they secrete various substances such as growth factors, 
cytokines, angiogenic factors, prostanoids, complement components and hydrolytic enzymes 
(28, 30, 34). Products from macrophages can effect both immune and non-immune cells (29) 
and give rise to a chronic inflammation in the peritoneal cavity (30). 
In women with endometriosis the peritoneal macrophages are increased in total number, 
concentration and activational status and some data suggest that they might even be more 
differentiated (28, 34, 46). The presence of endometrial cells in the peritoneal fluid enhances 
monocyte recruitment and activation (47). Macrophage products are increased in patients 
with endometriosis and can play a role in the initiation, maintenance and progression of 
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endometriosis (28, 34, 48) by affecting the survival and growth of ectopic endometrial cells 
(28, 29, 34).  
An increased sperm phagocytosis by peritoneal macrophages has been found in patients with 
endometriosis (49). Moreover, the scavenger receptor function in the macrophages might be 
defective and thereby their function to recognize cellular debris (29).   
Natural killer (NK) cells have been suggested to play a role in the clearance of regurgitated 
endometrial cells in the peritoneal cavity and women with endometriosis have NK cells with 
decreased cytotoxicity (29). This may increase the likelihood of implantation (34). NK cell 
activity is decreased in both peripheral blood and in PF of patients with endometriosis and 
the activity level is inverse related to the stage of the disease (42, 50).  
T-cells facilitate the cell-mediated immune response and their cytokines can affect B-cells, 
macrophages, NK cells and other T-cells. An increased T-helper to T-suppressor ratio has 
been noted in the PF in women with endometriosis, suggesting an impaired cellular immune 
activity (38). The data is inconsistent for changes in T cells concentration (28). 
  
1.1.6.2.3 Humoral immunity and endometriosis 
In patients with endometriosis there is evidence for alterations in B-cell activity and an 
increased incidence of auto-antibodies has been found in both serum and PF (29, 34). The 
increased immune autoimmunity may be due to enhanced reactivity to normal self-antigens 
because of a genetic predisposition or an excess of endometrial antigens in the peritoneal 
cavity (34). Although a strong genetic component exists in endometriosis, association with a 
specific HLA haplotype has not yet been demonstrated and the definition of endometriosis as 
an autoimmune disease has not been manifested (29, 34).   
 
1.1.6.2.4 Cytokines  
Cytokines are postulated to participate in the pathogenesis of endometriosis (28). The 
cytokines are multifunctional proteins with large properties and can be produced by 
peritoneal macrophages, lymphocytes, ectopic endometrial implants (epithelial and stromal 
cells) and from mesothelial cells lining the peritoneum (38). 
Cytokine activities include; proliferation and differentiation of immune cells; growth of 
connective tissue and endothelial cells; induction of release of hormones, enzymes, acute 
phase proteins and other cytokines; enhancement of various cytotoxic activities; regulation 
of immunoglobulin secretion and chemotaxis (28, 38, 42). Cytokines exert effects on a 
variety of cell types and act as key mediators of intercellular communication within the 
immune system (29).  
Patients with endometriosis have higher levels of several pro inflammatory cytokines in the 
PF, for example IL-1, IL-6, IL-8, MCP-1, TNF-α, VEGF and RANTES (29, 34, 38, 42, 51-
53).  
TNF-α (Tumour necrosis factor-α) is secreted from PF macrophages (28, 34). It enhances the 
adhesion of endometrial stromal cells to mesothelial cells, is embryotoxic and may affect 
sperm motility (28, 34). The level of TNF-α in PF is positively correlated to the level of 
menstrual pain (54) and the level decreases after medical treatment (53).  
IL-1 (Interleukin-1) induces prostaglandin synthesis, T-cell proliferation and stimulates B 
lymphocytes (28, 34). It may also have stimulatory effect on fibroblast proliferation and 
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collagen deposition suggesting a role in the pathogenesis of adhesions and peritoneal fibrosis 
in endometriosis (28, 34). The level of IL-1 in PF decreases after medical treatment (53). 
VEGF (vascular endothelial growth factor) is a potent angiogenic factor and activated 
macrophages are the major source of VEGF (55). The expression is regulated by ovarian 
steroid hormones (31, 56).  
RANTES (Regulated on Activation, Normal T Cell Expressed and Secreted) is produced by 
ectopic endometrium and is a selective chemo attractant for monocytes and T-cells (57). The 
concentration of RANTES is related to the severity of the disease (28, 34, 58).  
IL-6 (Interleukin-6) is secreted by macrophages, endometrial cells, ectopic endometrial tissue 
(both epithelial and stromal cells), lymphocytes, monocytes, fibroblasts, endothelial cells and 
keratinocytes (38, 42, 59). IL-6 acts on macrophages, B-cells and T-cells and regulates 
immune response by modulating the secretion of other cytokines and by acting as a growth 
regulator (29, 42). It stimulates angiogenesis, promotes proliferation and is related to tissue 
repair (28, 34, 38, 42, 60). Peritoneal fluid levels of IL-6 correlate well with the severity of 
endometriosis (29, 61, 62). Increased concentrations of IL-6 have been found in ectopic 
endometrial tissue culture of women with endometriosis (42, 53).  
IL-8 (Interleukin-8) is produced by monocytes, endothelial cells, fibroblasts, mesothelial 
cells and endometrial stromal cells (28, 29, 38). It stimulates angiogenesis, inflammation and 
proliferation in numerous cells including endometrium and endometriotic stromal cells (28, 
38, 42, 48, 51, 63). The levels of IL-8 in the peritoneal fluid are correlated with the severity 
of endometriosis (38, 64). IL-8 is thought to play a role in the pathogenesis and maintenance 
of endometriosis by inducing the attachment of endometrial cells to fibronectin (38, 57) and 
by acting as an autocrine growth factor in the endometrium (29). 
MCP-1 (Monocyte chemotactic protein-1) is secreted by endothelial cells, mesothelial cells, 
monocytes/macrophages, fibroblasts, leukocytes and by both epithelial and stromal cells in 
endometrial tissue (29, 65-68).  It is a potent chemotactic and activating factor for monocytes 
and attracts, activates and stimulates macrophages to secrete growth factors and cytokines 
(28, 42, 65, 69) but also stimulate endometrial cell proliferation (42, 69). The levels of MCP-
1 in the PF are correlated to the severity of the disease and medical treatment with 
gonadotropins suppresses the concentrations (69).  
 
1.1.6.3 The role of peritoneum 
The peritoneum can be more or less receptive to implantation of endometrium and the risk 
for development of endometriosis could to some part depend on peritoneal factors (30). The 
peritoneum consist of a thin layer of connective tissue covered by a layer of mesothelium 
(42) and is highly permeable for small molecules. The total surface area is around 2 m2 or 
about equal to that of the skin (28, 31). The mesothelial cells of the peritoneum produces IL-
1, IL-6, IL-8, MCP-1, G-CSF, M-CSF and CA-125 and are suggested to play a role in the 
regulation of peritoneal inflammation and tissue regeneration (28). 
 
1.1.6.4 The fallopian tubes 
Women with endometriosis have a uterine hyperperistalsis that differs significantly from the 
peristalsis of healthy controls. The defect uterine contractions can participate in the 
pathogenesis of endometriosis by increasing the risk for retrograde menstruation but even be 
an explanation for the impaired fertility since the sperm transport might be defect (70). 
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1.1.6.5 Pathophysiology behind symptoms 
 
1.1.6.5.1 Pain 
The pain in patients with endometriosis can be of several different kinds, each of which 
might have different pathophysiology. The explanation of the increased pelvic pain involves 
inflammatory substances and increased density of sensory nerves fibres in the endometriotic 
lesions and the eutopic endometrium (71-73). Effects of active bleeding from endometrial 
implants and anatomical distortion caused by adhesions and fibrosis have also been 
suggested (8, 10, 16).  
Peritoneal endometriotic lesions may cause all symptoms but deep infiltrating endometriosis 
and extensive adhesions may cause more severe pain (17, 31). Correlations have been found 
between pain severity and both the depth of infiltration into peritoneum or pelvic organs and 
the pro-inflammatory substances released by the implants into the peritoneal cavity (10, 71). 
The pain level seems to be associated with the distance between nerve fibres and implants 
and the number of nerve fibres within lesions (74, 75). Increased amounts of sensory nerve 
fibres have been found in peritoneal endometriotic lesions and in the functional layer of the 
eutopic endometrium in patients with endometriosis compared to peritoneum and 
endometrium of healthy women (76, 77). Hormonal treatment with oral contraceptives (OC) 
or progestogens significantly reduced nerve fibre density in endometrium, myometrium and 
peritoneal lesions (78, 79). Another study showed correlation between the occurrence of 
nerve fibres in ovarian endometriotic lesions and pain intensity (80). In addition,  women 
with endometriosis have a higher density of neuroendocrine cells in the endometrium (81).   
Thus, inflammatory substances and substances produced by neuroendocrine cells can 
sensitise and/or activate the sensory nerve endings (82) and contribute to the pain in 
endometriosis. A sensitisation of sensory nerve fibres can also produce a central sensitisation 
which is a long-lasting hyper excitability of neurons in the central nervous system (71).  
 
1.1.6.5.2 Subfertility 
Distortion of the anatomy and/or adhesions causing occluded fallopian tubes are  
understandable factors causing infertility but mechanisms underlying reproductive failure in 
minimal endometriosis remain controversial (3). Mechanisms investigated include altered 
folliculogenesis, ovulatory dysfunction, reduced steroid production of granulosa cells, 
defects in luteal phase function and alterations within the oocyte (41). Other mechanisms 
investigated are sperm phagocytosis, anti-sperm antibodies, impaired fertilisation, 
decreased capability of fimbrial ovum capture, toxicity against early embryonic 
development and defective implantation (41).  
Cytokines and the immunologic alterations in the PF are believed to be related to 
endometriosis-associated infertility and can affect all the above functions (11, 28, 29).  
A reduced oocyte and embryo quality with impaired fertilisation, embryo cleavage and 
implantation rate has been found in patients with endometriosis (83, 84) and women with 
endometriosis have approximately 50% lower fertility frequency after IVF compared to 
women with tubal defect (3, 85, 86). Moreover, endometrial changes and an altered uterine 
and tubal contractility have been suggested to be involved in the endometriosis-associated 
infertility by affecting normal sperm transport and the implantation process (11, 83, 87). 
   9 
An increased sperm phagocytosis by macrophages has been found in the PF of patients with 
infertility and endometriosis (49) and the PF also decreases the sperm velocity and the 
proportion of motile spermatozoa when added to medium in vitro (28, 29, 34). Abnormal 
autoantibodies are thought to play a role in the endometriosis-associated infertility by 
affecting the implantation (29, 34, 88).  
Most data suggest that endometriosis affect fertility via the oocyte/embryo and not through 
the endometrium (3) since no differences in pregnancy, implantation and live birth rate were 
seen between healthy women and women with endometriosis who received oocytes from a 
single healthy donor (83).  
The risk for miscarriage is not increased in women with endometriosis (11, 89, 90) but the 
rates of pregnancy loss after IVF are higher (6). 
 
 
1.1.7 Treatment 
There are several treatment options for women with endometriosis aiming to relieve pain 
and/or ameliorate infertility but none of them are curative (16). Pharmacological and surgical 
therapies are available, can be combined and can improve patients physical functioning, 
psychological functioning, vitality, pain level and general health (2). Surgical treatment 
followed by medical therapy offers longer symptom relief than surgery alone (8, 10). 
Medical therapy can be initiated for pain control without surgical confirmation of 
endometriosis (8) and is recommended by both American College of Obstetricians and 
gynecologists and Royal College of Obstetricians and Gynaecologists (13).  
The risk of pain recurrence after completion of treatment is high for all treatments and may 
be as high as 50% after 12-24 months (9). The stage (ASRM) or morphologic types of 
lesions do not predict the response to therapies for pain or infertility (8, 91). 
 
1.1.7.1 Analgesics 
NSAIDs (non-steroidal anti-inflammatory drugs) suppress the synthesis of prostaglandins 
and can relieve dysmenorrhea (16). No significant reduction in pain due to endometriosis 
was shown in a small RCT when NSAIDs was compared with placebo and no superiority of 
one NSAID over another (8, 92). 
 
1.1.7.2 Hormonal treatment of pain 
Hormonal treatments aim to lower the concentration of circulating oestrogen and thereby 
suppress the stimulatory effect on endometriotic lesions, leading to quiescence and 
regression of active lesions (16). All hormonal treatments suppress ovarian activity, reduce 
menstrual bleeding and induce decidualisation and atrophy of endometriotic implants at 
various extents (9, 10, 16). Complete down-regulation of ovaries and hypo-oestrogenaemia 
does not seem to be crucial and achievement of amenorrhea seems to be sufficient (93).  
All hormonal treatments are contraceptive and include oral contraceptives, progestogens, 
androgenic agents and gonadotropin releasing hormone (GnRH) analogues (9). All hormonal 
treatments are similarly effective in relieving pain but the side effects differ (8, 9, 16, 94). 
During hormonal treatment 60-100% of patients get pain relief (8, 9, 16, 94) but the chances 
for spontaneous pregnancy do not improve (8, 11). Endometriotic cysts are not amenable to 
medical treatment even if a temporary reduction in size may occur (9, 10). 
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1.1.7.2.1 Combined oral contraceptives 
Combined oral contraceptives (OC) can be used cyclically or continuously for pain related to 
endometriosis (10, 16). 75-80% of patients gets pain relief from OC and a continuous use 
can further improve the effect (8). Side effects include nausea, weight gain, fluid retention, 
depression, breakthrough bleeding, breast tenderness and headache (8). The treatment can be 
used long term and also the contraceptive ring or a transdermal patch can be used (9, 16).  
 
1.1.7.2.2 Danazol  
Danazol acts primarily by inhibiting luteinizing hormone surge and steroid genesis and by 
increasing free testosterone levels (10). Danazol was an early treatment for endometriosis but 
its androgenic and anabolic side effects limit its clinical usefulness even if the effect on pain 
is comparable to other hormonal therapies (8). Side effects include weight gain, oedema, 
bloating, acne, lipid profile alterations, hirsutism and skin rashes (8, 9, 16). The treatment 
can be used for 6-9 months (9).  
 
1.1.7.2.3 Progestogens 
Oral progestogens used for treatment of endometriosis include medroxy progesterone acetate 
(MPA, Provera®), Noretisteron (Primolut-Nor®), Desogestrel (Cerazette®), Dienogest 
(Visanne®) and Cyproterone acetate (16). MPA is the most used and the effect on pain equal 
with OC (8). The treatment can be long term and the inter-individual variation in dosage is 
large (95). The side effects include nausea, weight gain, bloating, depression, fluid retention, 
acne, headache, breast tenderness, irregular bleeding or breakthrough bleeding and the return 
of ovulation may be delayed after treatment has stopped (8, 9, 16).  
The levonorgestrel intrauterine system (LNG-IUS) can be used long term and suppresses the 
endometrium and even the ovaries in some women (9). Similar effectiveness on pain as 
GnRH agonists has been shown (9, 16) but the exact mechanism is unknown since it does 
not inhibit ovulation and does not induce a hypo-oestrogenic state (in serum) (16).  
Postoperative treatment with the LNG-IUS after conservative surgery, diminish 
dysmenorrhea and non-cyclic pelvic pain but not dyspareunia (8, 9, 16). A significant 
decrease in the extent of disease has been found when observed at a second look laparoscopy 
after six months treatment with LNG-IUS (10, 16).  
 
1.1.7.2.4 Gonadotropin releasing hormone agonists (GnRH agonists) 
GnRH agonists are a second line treatment after OC or progestogens have failed and can be 
used for 6 months (9, 16). They deplete the pituitary of endogenous gonadotropins and result 
in very low local and circulating oestrogen levels causing endometrial atrophy and 
amenorrhea (8, 9, 16). The side effects include vaginal dryness, hot flushes, psychiatric 
symptoms, decreased libido, irritability/mood swing, headache and reduced bone mineral 
density (8-10, 96). Add-back therapy with a low dosage oestrogen-progestogen is 
recommended to maintain bone mineral density and does not affect the efficacy on pain 
symptoms (8, 16). A follow up study of patients treated with GnRH agonists alone for six 
months revealed a 53% recurrence of disease/symptoms two years after treatment (10). The 
need for subsequent therapies was 37-74% five years after GnRH treatment (97). 
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1.1.7.1 Surgical treatment of pain 
Surgical procedures are indicated to alleviate pain symptoms (16). Procedures include 
excision, fulguration or laser ablation of endometriotic implants, excision or drainage of 
endometriotic cysts, resection of rectovaginal nodules, lysis of adhesions and interruption of 
nerve pathways (8). Laparoscopic destruction of endometriotic implants is associated with 
significant reduction in pain compared to diagnostic laparoscopy (8, 98, 99). Laparoscopic 
excision of invasive endometriosis improved pelvic pain, dysmenorrhea, dyspareunia, rectal 
pain but also significantly improved quality of life (23). One year after surgery the pain relief 
ranges between 50 and 95% (10) but pain recur within 6-12 months in 30-60% of patients (8, 
94) and in up to 75% of women within 2 years after surgery (6). At laparoscopic follow up 
after one year, recurrent disease was revealed in 44% of patients (10). Surgical treatment 
followed by medical therapy (GnRH agonists, Danazol or OC) offers longer symptom relief 
than surgery alone (8, 10, 96). 
The addition of LUNA (laparoscopic uterine nerve ablation) to laparoscopic surgical 
treatment is not associated with a significant difference in outcome (8, 10, 100). Pre-sacral 
neurectomy has proved to be superior to laparoscopic ablation alone for treatment of 
dysmenorrhea but there is insufficient evidence to recommend this treatment (101). 
Surgery is the primary approach for symptomatic and/or large endometriotic cysts (10, 102) 
and excision/enucleation of the cysts has better long time effect on pain and lower recurrence 
rate compared to drainage and ablation (8, 10, 103).  
A pain relief can be provided in 80-90% of women after hysterectomy with bilateral 
salpingo-oophorectomy but pain was reported to recur in 10% of the women within 1-2 years 
(8). Hysterectomy with bilateral salpingo-oophorectomy is more effective than hysterectomy 
alone (104). A hormone replacement therapy with both oestrogen and progesterone is 
recommended for patients severely suffering from post-surgical menopause to lower the risk 
for recurrence of endometriosis as compared to oestrogens alone (8, 10, 105).  
 
1.1.7.2 Treatment of infertility 
Medical treatment (with OC, GnRH agonists, progestogens or Danazol) does not improve 
the chances for spontaneous pregnancy in women with endometriosis (8, 11, 16, 106).   
Ablation of endometriotic lesions and lysis of adhesions improves fertility modestly in 
minimal endometriosis (8, 11, 89, 107, 108). The effect on spontaneous pregnancy favours 
excision of the endometriotic cysts as compared to drainage and ablation (103).  
Artificial reproductive technologies (ART) are beneficial and include controlled ovarian 
hyperstimulation and intrauterine insemination or IVF and embryo transfer (6).  
Ovarian hyperstimulation with clomiphene citrate and insemination improves the chances for 
pregnancy in women with endometriosis and conservative surgery further improves the 
outcome, but the treatment is still least successful compared to healthy women (11).  
IVF is the most effective treatment for infertility in patients with endometriosis (11). 
Women with endometriosis are less likely than women with tubal factor infertility to 
conceive by means of IVF (8) and the success rates after IVF decreases with a more severe 
disease (11). Long luteal suppression with GnRH agonists for 3-6 months before IVF 
treatment seem to increase live birth rate compared to shorter down regulation (8, 11, 109). 
Continuous oral contraceptives for 6-8 weeks seem to be equally effective (16). 
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There is not sufficient evidence of an effect on reproductive outcome after surgical treatment 
of endometriomas compared to expectant management before fertility treatment and ovarian 
surgery may diminish ovarian reserve (6, 8, 16, 103, 110). 
 
1.1.7.3 Experimental therapies and new approaches 
Large efforts are being made in the development of new therapies for the treatment of 
endometriosis. The new approaches include modulators of angiogenesis and of the immune 
system, agents affecting steroid receptors, inhibitors of the local steroid production, GnRH 
antagonists, statins, antioxidants and agents that inhibit matrix metalloproteinases in the 
endometriotic tissue (6, 10).  
Some immune modulatory drugs have been tried in the treatment of endometriosis.  
Anti-TNF α (Infliximab®) can inhibit the inflammation process and is used in the treatment 
of Crohn´s disease and Rheumatoid arthritis (16). A Cochrane review updated in 2012 could 
not reveal evidence to support the use of anti-TNF α drugs in the management of women 
with endometriosis for the relief of pelvic pain (111).  
Pentoxifylline is a xanthine derivative used for arterial sclerosis to improve vascularisation 
(16). The substance has anti-inflammatory activity and has been tried for the treatment of 
pain and infertility in patients with endometriosis (10). A systematic review from 2009 based 
on four trials could not find enough evidence to support the use (112). 
Aromatase inhibitors (AI) inhibit oestrogen production selectively in endometriotic lesions, 
without affecting ovarian function (9) and is currently used for breast-cancer treatment.  
Endometriotic lesions express aromatase and synthesize their own oestradiol and suppression 
of ovarian oestradiol production may not completely control pain (6, 16). For women in 
reproductive years AI induce ovulation (8) and should be used together with other hormonal 
treatments (16). In reproductive-age women, the combination of AI with conventional 
therapy alleviates endometriosis-related pain and in postmenopausal women, using an AI 
alone has been shown to be an effective treatment (113). The doses used are lower than those 
used for breast-cancer treatment and the effect on pain seems to be similar to those of other 
hormonal therapies (8). Adverse effects include hypo-oestrogenism with hot flushes, joint 
and muscle pain, headache and negative impact on bone mineral density (16).  
Selective progesterone receptor modulators aim to correct the progesterone resistance of 
endometriotic implants (6, 8). Anti progestagens such as mifepristone have been shown to 
reduce pain in small studies with 9 and 7 patients, but data from large randomised trials are 
lacking (8). Ulipristal acetate used for pre-surgical treatment of uterine fibroids (Esmya®) 
and for emergency contraception (ellaOne®) is a selective progesterone receptor modulator 
under developement for use in endometriosis (8). Asoprisnil, a progesterone receptor ligand 
and telapristone acetate, a progesterone receptor antagonist are currently studied but results 
are not yet published (16).  
Oral GnRH antagonists can induce a dose-dependent decrease in oestrogen levels and are 
under development (16).  
Acupuncture, TNS, hypo gastric nerve block and physical therapy has been proposed but 
data from large randomised trials are lacking (8). 
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1.2 BACKGROUND LIGNOCAINE  
 
1.2.1 Introduction 
The first local anaesthetic (LA) substance in clinical use was cocaine, an ester-type local 
anaesthetic isolated in 1860. Procaine was developed in 1904 and became the dominating 
LA until 1943 when lignocaine, the first amide-type LA was synthesised. Many LAs have 
been developed after lignocaine with focus on nerve-blocking effects, duration of action and 
safety. No ester-type LA have been evolved after 1948 because of larger allergenic potential 
and since the amino ester-link is more instable (114).  
Lignocaine in high concentration has the ability to block sodium channels, thereby blocking 
membrane excitability and the generation of action potentials (115) and is used for local and 
regional anaesthesia and for antiarrhythmic treatment. In the last two decades, other 
beneficial effects of LAs, such as their anti-inflammatory properties, have been investigated.  
 
1.2.1 Anti-inflammatory effects of local anaesthetics 
Membrane actions of LAs occur not only in excitable membranes but also in non-excitable 
membranes (115, 116). Inhibition of receptors others than Na+ occur at much lower 
concentrations, some-times 1000-5000-fold lower (116). In lower concentrations, lignocaine 
has effects on the inflammatory response and especially on inflammatory cells (116, 117). 
Most data on anti-inflammatory properties of LA is based on experimental in vitro and in 
vivo studies (115). 
 
1.2.1.1 Anti-inflammatory effects in vitro 
All LAs penetrates the cells and exerts similar therapeutic and anti-inflammatory effects (115, 
118). The racemic ropivacaine is the only LA that lacks or has only weak anti-inflammatory 
properties (115, 119). The substances have effects on several cell functions including collagen 
synthesis, adhesion to the endothelium, cell motility, NK-cell mediated cell lysis, phagocytosis 
and the release of inflammatory mediators (119, 120).  
LAs induce reversible, conformational and functional alterations of the cell membrane, making it 
more stable (115, 117, 121, 122). They seem to interact with membrane proteins and lipids, thus 
interfering with ion channels (K+ and Ca2+) and inhibiting the ion exchange (114, 115, 120).  
Inhibition of intracellular calcium flux may be an important shared mechanism of LAs action on 
cytokine release and intracellular mechanisms (115, 122, 123). In addition, LAs seem to interact 
with membrane bound enzyme activity and with the cytoskeleton of the cell (114, 115, 120). The 
substances can inhibit signalling of G-protein coupled receptors mediating inflammatory 
response and signalling of muscarinic acetylcholine receptors (116, 124). Effects have also been 
demonstrated on the cytokine intracellular signalling pathways (122).  
In leukocytes, LAs inhibit adhesion to the endothelium, motility, the release of lysosomal 
enzymes, activation and priming of neutrophils and granulocyte phagocytosis (115, 116, 125). 
The substances have repressive effects on spontaneous prostaglandin biosynthesis, the release of 
thromboxane B2, leukotriene and histamine and the production of superoxide anion and 
hydrogen peroxide (115, 116, 126). Lignocaine can inhibit NK cell activity and suppress 
eosinophil responses to IL-5 (122, 127). 
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Lignocaine inhibit macrophage motility (121) and can induce a dose-dependent and 
reversible inhibition of phagocytosis in macrophages and monocytes (115, 116). In studies of 
peritoneal macrophages in vitro, the presence of lignocaine reduced the phagocytosis of 
spermatozoa (128). Lignocaine has been shown to decrease cytokine release from 
macrophages both in vitro and in vivo (116, 122). It is not known whether the suppressed 
cytokine release is due to reduced expression and synthesis of the cytokine or decreased 
cellular secretion (122). However, in one study lignocaine reduce the induced MCP-1 
production in human monocytes on both protein and mRNA level and even the cell 
migration and the peak of cytosolic free Ca2+ were dramatically reduced (129). The release 
of IL-1 by human monocytes was inhibited by lignocaine and bupivacaine (115, 116, 130). 
Moreover, lignocaine has been shown to inhibit oxidative metabolism in human alveolar 
macrophages (116).  
Lignocaine attenuated the concentrations of endothelial IL-1β, IL-6 and IL-8 in an in vitro study 
with endothelial cells (131). In intestinal epithelial cells, lignocaine inhibited the secretion of IL-
8 and IL-1β and also the transcription of IL-8 mRNA was reduced (118). In endothelial and 
smooth muscle cells lignocaine attenuated cytokine-induced cell-injury and the effect was 
suggested to be modulated by mitochondrial KATP channels (125).  
  
1.2.1.2 Anti-inflammatory effects in vivo 
The inflammatory response should protect from tissue damage but an exacerbated 
inflammatory response rather destroys. The anti-inflammatory effect of lignocaine have been 
proposed as treatment in various clinical conditions to inhibit tissue damage (123). In animal 
studies, lignocaine have been beneficial in the treatment of lung injury, septic shock and 
myocardial infarct (115, 122). Lignocaine accelerates re-epithelialisation and improves 
wound healing (115). Several studies on rats have shown neuroprotective effects of 
lignocaine at antiarrhythmic doses (119). In rabbits, lignocaine attenuated the increase in 
plasma IL-6 and IL-8 concentration induced by intravenously endotoxin administration (132) 
and inhibited the release of IL-1 and TNF-α in bronchoalveolar fluid from endotoxin-injured 
lung (118, 133). 
In human studies lignocaine have been used as enemas for treatment of ulcerative colitis 
and the treatment, thought to affect both the nerve cells and the intestinal inflammation, 
had a high success rate (120). Topical and intravenous lignocaine has been shown to 
reduce inflammation and pain after burn injuries and topical lignocaine-prilocaine cream in 
the prodromal stage of herpes simplex could be useful (115). Infusion with lignocaine 
significantly decreases the incidence of neurological decompression sickness post dive and 
also shortens the time for recovery of bowel function after surgery (119). Besides, 
lignocaine has been used for interstitial cystitis (115). In fertility therapy, lignocaine has 
increased the pregnancy rate when pertubated pre-ovulatory (134, 135). An unexpected 
side effect was a pain relief in some patients with endometriosis (135). The effect seen on 
fertility might to some extent be explained by the anti-inflammatory properties of 
lignocaine but can also be an effect of tubal flushing (136). A small study investigating the 
effect on pain showed promising results since five of six women with endometriosis 
reported decreased pain level after pertubation with lignocaine 1,0 mg/ml (137). 
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The anti-inflammatory effect of local anaesthetics is prolonged and persist after serum 
levels have decreased (116). 
 
1.2.1.1 Other effects of local anaesthetics 
LAs in millimolar concentrations possess anti-microbiological properties in vitro and in vivo 
(116) but the mechanisms of action for these effects are still unclear (115, 116). All LAs has 
antimicrobial effects except for Ropivacaine, which has weak antimicrobial properties (115, 
119). In addition,  the substances have antifungal (115) and antiviral effects in high 
concentrations (116). LAs also have anti-thrombotic actions (124). 
LAs prevent axonal sprouting which might be important in the management of pain together 
with effects on ion flux and G-protein coupled receptors (114). Both nociceptive and neuropathic 
pain are targeted by local anaesthetics (114). 
 
1.2.2 Safety 
The adverse effects of lignocaine have been well investigated and manifests most commonly 
on the central nervous and cardiovascular systems (138, 139). Subjective toxic effects on the 
central nervous system (CNS) appear at concentrations above 3-5 µg/ml and include nausea, 
dysphoria, drowsiness and cardiovascular instability (116, 138). Objective adverse 
manifestations appear at concentrations above 6-10 µg/ml and include disorientation, 
muscular irritability, respiratory depression, seizures/convulsions and coma (116, 138). 
Plasma concentrations of lignocaine above 10 μg/ml can affect the cardiovascular system 
with symptoms such as bradycardia, atrioventricular blockade and cardiac arrest (116). Both 
hypotensive and hypertensive reactions can occur (116). Serum-levels above 20 μg/ml are 
required to induce cardiac arrest (138, 140).  
Data from the 1960th suggest that large amounts of lignocaine may be infused intravenously 
before toxicity is produced and the largest dosage in these studies were 200 mg (141). An 
intravenous (iv) bolus of 2 mg/kg lignocaine results in peak plasma levels of 1,5-1,9 µg/ml 
and continuous iv infusion of lignocaine 2-4 mg/min leads to plasma concentrations of 1-3 
µg/ml after 150 min (116). Serum levels of local anaesthetics after non-vascular 
administration correspond with the vascularity of the tissue (114, 140). Rectal application 
of 400 mg lignocaine resulted in maximal plasma concentration 0,5-1,9 µg/ml after 2 h 
(120). Small molecules like lignocaine hydrochloride with a molecular weight of 271 Da 
diffuse rapidly through the peritoneum (28, 31). In a review of systemic levels of LAs after 
intraperitoneal application, nine trials where lignocaine were used were found (139). The 
dosage used varied from 100 mg-1000 mg and the time to maximum concentration (Tmax) 
in serum ranged from 5 to 40 minutes for plain lignocaine. Mean concentration maximum 
(Cmax) ranged from 1.01 µg/ml to 4.32 μg/ml and the highest observed value was detected 
after intra peritoneal administration of 400 mg lignocaine (142). No report of serum or 
clinical toxicity was found in any of the reviewed studies (139). 
Tissue toxicity, primary myotoxicity and neurotoxicity can be produced by all LAs if “high” 
concentrations are used but true allergic reactions are associated only with amino ester-
linked LAs (114). 
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The anti-inflammatory properties of LAs might in theory increase the susceptibility to 
infections but this has not been relevant in the in vivo studies reported to date except in 
settings of gross bacterial contamination (116). LAs seem to be able to modulate excessive 
inflammation without significant impairment of host defences (116) and no increased 
infection rate attributable to an anti-immune effect of LAs has been demonstrated (122). LAs 
selectively inhibit the priming of polymorphonuclear cells and prevent overactive 
inflammatory responses without impairing host defence or suppressing normal inflammation 
(119). Patients treated with lignocaine are not more susceptible to infections (119). 
Lignocaine passes through the placenta (143) and human foetus and newborn have the ability 
to metabolise lignocaine to the same extent as adults (143). No embryotoxic effects of 
lignocaine have been found in rats (143) but no studies regarding embryo toxic effects of 
lignocaine in humans have been conducted. Lignocaine has been used in numerous women 
during pregnancy and there is no evidence supporting that lignocaine could disturb the 
reproduction process according to FASS (the Swedish Pharmacopeia Drug Information) and 
JanusInfo (Interface Management of Pharmacotherapy).   
 
1.3 PATIENT REPORTED OUTCOMES 
 
1.3.1            Definition 
Patient reported outcomes (PRO) are measurements based on a report that comes directly 
from the patient about their health condition. PRO includes Quality of life (QOL) which has 
been established as an important end-point in clinical trials. QOL is a multidimensional and 
subjective concept including physical, social, and psychological functioning. Health status, 
functional status and QOL are concepts often used interchangeably to refer to the same 
domain of health. However, patients distinguish between QOL and health status which are 
perceived as two distinct constructs (144). When rating QOL patients give greater emphasis 
to mental health than to physical functioning and the pattern is reversed for appraisals of 
health status (144). Health related quality of life (HRQL) is often used and encompasses 
physical, emotional and social aspects associated with a disease or its treatment (145, 146). 
 
1.3.2 Quality of life questionnaires 
There are several questionnaires for evaluating HRQL and the questionnaires could be 
generic or disease specific. Generic instruments are intended for general use and enables 
comparison across disease groups. Disease-specific questionnaire are meant for use in a 
specific disease area and are more sensitive and responsive to change than the generic 
instruments (146, 147). For endometriosis, three disease specific questionnaires have been 
developed by Bodner 1997 (148), Colwell 1998 (145) and Jones 2001(146). 
For use in clinical trials a questionnaire should be valid, reliable, sensitive and responsive to 
change (149, 150).  Validity means that the questionnaires measure what they are intended, 
and appear, to measure (151).  Reliability means that the scale yields reproducible and 
consistent results and can discriminate between better and worse HRQL within and between 
individuals (151). Internal reliability measures homogeneity of items within a scale or the 
precision of a scale (152). Sensitivity is the ability to detect clinically relevant differences 
between groups, for example between two treatment groups in a randomised clinical trial and 
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is evaluated indirect through data quality (147). Responsiveness measures how sensitive the 
questionnaire is to detect and describe changes in patients’ health status over time (153). 
Responsiveness refers to the instruments ability to detect small but important changes with 
feasible sample sizes and can be seen as an aspect of construct validity (150). 
 
1.3.3 Evaluation of responsiveness 
Responsiveness must be demonstrated and documented for the particular study population and it 
is highly recommended to confirm responsiveness across multiple samples (150). The 
responsiveness is evaluated through data quality by longitudinal assessment of patients in whom 
a change is expected to occur (147, 150). Some criteria or “anchors” are needed to identify 
whether patients have changed over time and should have relationship with the PRO measure 
(150). Responsiveness can be determined by comparing the questionnaire to a generic health 
status questionnaire with established responsiveness or by using patient-rated global 
improvement i.e. transition questions (153). A transition question requires the respondent to 
evaluate the change in their clinical status or their health status by answering the response 
categories much better, somewhat better, about the same, somewhat worse and much worse (150, 
153). 
Two of the most widely used measures of responsiveness are the Effect size (ES) and the 
Standardised response means (SRM) (147, 150). Also the Index of responsiveness can be 
used (145, 150, 153). There is controversy as to which is the best measure to use for 
evaluating responsiveness and the preferred index is unclear (147). All these statistics is the 
observed amount of changes over the observed amount of variation (152). 
Effect size (ES) is one of the most commonly used methods for interpreting change in a score  
and is an estimation of the magnitude of change in health status between two different times 
(154, 155). ES is independent of sample size and the standardized mean difference (d) calculated 
as Cohen d is the standard measurement for effect size. Cohen d is calculated by dividing mean 
difference with the pooled standard deviation (SD) (147, 156). The pooled SD represents the root 
mean square of the two standard deviations. An effect size of 0.2 indicates small change, 0.5 
indicates a moderate change and 0.8 a large change as proposed by Cohen et al. (156). The ES 
index gives information about the size of an effect in terms of SD units. An ES of 0.0 indicates 
that the mean of the treated group is at the 50th percentile of the untreated group and an ES of 0.8 
indicates that the mean of the treated group is at the 79th percentile of the untreated group (156). 
The standardised response mean (SRM) is the ratio of the mean changes to the SD of that change 
i.e. mean change on a scale divided with the mean change in SD (147, 153). An SRM >0.5 is 
considered to be responsive (151). 
Index of responsiveness is the ratio of the average change score in those with improvement 
(or deterioration) to the SD of the change in the stable group (145, 151). An index of 
responsiveness greater than 1.0 is considered indicative of a measure highly responsive to 
change, whereas a value of 0.2 or more is considered acceptable (145, 153, 157).  
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To evaluate responsiveness, one can also compare differences in changes in the scores across 
different groups (i.e. stable versus moderate improvement) (150, 158). For evaluating the 
significance of change scores a paired t-test can be used (153, 158). 
 
All of the above methods are based upon means and SD, with an implicit assumption that the 
data follow a normal distribution. Many QOL scales have a non-normal distribution, in 
which case medians and interquartile ranges (IQR) may replace means and SD (147, 159). 
Unfortunately little work has been carried out into this subject (147). Moreover, it should be 
noted that some scales are not only non-normal, but may also suffer from “ceiling effects” in 
which a large number of patients place responses in the maximum category (147). This can 
compromise sensitivity and responsiveness (147, 151). 
 
1.3.4 Evaluation of data quality 
Floor and ceiling effects refer to the extent to which patients score at the extreme ends of the 
questionnaire and are considered to be present if >15% of respondents achieved the lowest 
(floor) or highest score (ceiling) (160, 161). If all patients score at extreme ends, it is not 
possible to detect an improvement or deterioration. The data quality also consists of 
evaluation of missing items in percent and gives an indication of whether the questionnaire is 
acceptable and understandable to the respondents (161). 
 
1.3.5 Questionnaires to be used in endometriosis 
Outcome measures for use in international clinical trials in endometriosis with regard to pain 
symptoms were established on an international meeting convened by the National Institutes 
of Health (NIH) and ASRM. Ratings on an 11-point NRS (Numerical/numeric Rating Scale) 
such as the VAS-scale, was recommended as primary outcome measures (74). For secondary 
outcome measure they proposed the Biberoglou and Behrman scale (categorical, 0-3) and the 
Endometriosis Health Profile-30 (EHP-30) questionnaire (74). A definition of responders 
was suggested to be either a 30% or a 50% reduction in symptoms (74). 
 
1.3.5.1 The VAS-scale 
The visual analogue scale (VAS) scale is ranging from 0 i.e.no pain to 100 corresponding to 
the worst pain imagined. The VAS scale is a valid instrument for evaluating chronic pain 
during endometriosis (74, 162). It is easy to administer and score, is sensitive to treatment 
effects and correlates with other intensity measures (74).  
There are few studies defining the clinical relevant improvement on the VAS scale. In 2010 
Gerlinger et al. tried to define a minimal clinically important difference for endometriosis-
associated pelvic pain. In that study, based on two small but randomised controlled trials, 
they found that the best separation between women rating themselves “minimally improved” 
and “improved” was a decrease of 28 mm on the VAS scale (163). The VAS scale is 
considered to be an ordinal scale and non-parametric statistics should therefore be used. 
 
1.3.5.2 The Biberoglou and Behrman scale 
The Biberoglou and Behrman scale from 1981 (164) has been widely used in clinical studies 
but have considerably limitations. It asks the patients about function and is not a pain scale. 
The scale include three symptoms; dysmenorrhea, dyspareunia and chronic pelvic pain, 
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graded on a scale from 0-3. Also, pelvic tenderness and induration at examination is 
evaluated by the physician on a scale from 0-3. A standard is lacking for the symptoms that 
will indicate that a treatment has succeeded (74). The Biberoglou and Behrman scale has not 
been used in a consistent manner and has never been validated or shown to be reproducible 
(74). 
1.3.5.3 The EHP-30 
The Endometriosis Health Profile-30 (EHP-30) questionnaire is the only QOL scale that has 
been validated for use in women with endometriosis (74). The questions in the EHP-30 
questionnaire were patient-generated and the questionnaire has proved to be reliable, valid 
and responsive to change (146, 153, 161). When the responsiveness of the EHP-30 was 
initially evaluated, complete data were obtained for 40 patients, and the study showed that 
only the social support scale on the core questionnaire failed to demonstrate any 
responsiveness (153). Responsiveness has thereafter been demonstrated for all scales in a 
larger sample of 228 women in the Netherlands (165). The EHP-30 questionnaire has been 
shown to be more responsive to change compared to the generic tool Short Form-36 (SF-36) 
in patients with endometriosis (153, 166).  
The EHP-30 questionnaire comprises two parts: a core questionnaire, which consists of five 
scales (pain, control and powerlessness, emotional well-being, social support and self-image) 
with a total of 30 items applicable to all women with endometriosis. The other part is the 
modular questionnaire, which does not necessarily apply to all women with endometriosis. It 
consists of six scales (work life, relationship with children, sexual intercourse, infertility, 
medical profession and treatment) and contains a total of 23 items (167). Within the scales 
the items are summed to create a raw score and each scale is then translated into a score 
ranging from 0 (best health status) to 100 (worst health status). All scores should be 
presented separately (168). The EHP-30 questionnaire is acceptable and understandable to 
the respondents indicated by high rate of data completeness and has low floor and ceiling 
effects (161). 
 
1.3.6 How to interpret the results from PRO 
To be able to interpret results from a clinical trial including PRO and HRQL, the 
questionnaire have to be valid, reliable, sensitive and responsive to change (149). The 
questionnaire also needs to be acceptable and understandable to the respondents and have 
interpretation guidelines, for example minimal important difference (MID) (150). 
 
The Minimal important differences (MID) can be defined as the smallest difference in score 
that the patients perceive as a change and can be used to interpret HRQL outcomes in clinical 
trials (169, 170). MID is the subjective significant change and a threshold  that demarcates 
trivial from small but important differences (171). The MID may vary by population and 
context and no one MID will be valid for all study applications involving a PRO instrument 
(150, 171). Both responsiveness and MID must be demonstrated and documented for the 
particular study population (150). The MID of a HRQL instrument can be estimated using 
within-patient global ratings of change (170).   
 
The effect of any treatment should be expressed in terms of both statistical significance and 
clinical relevance. Statistical significance testing is depending on both the size of the effect 
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and the size of the sample and is the golden standard for interpreting results in clinical trials. 
However, a significant change does not mean that the change is clinically important and can 
be perceived by the patients. Whether or not an effect is clinically meaningful should be 
determined by the patients (74). Effects of an intervention on health status should ideally be 
analysed in two ways; as mean differences between patient groups in the change in scores 
and as the difference in the proportion of patients in both groups exhibiting clinically 
significant change as defined by the MID (151, 169). Even if the mean difference between 
treatment and control group is less than the MID, treatment may have an important impact 
on many patients (172). Investigators are recommended to report the estimated threshold and 
either a change in score or an absolute score obtained can be referred to (169, 170).  
 
Using effect sizes can be a way to interpret changes in health status and can assess the 
magnitude and meaning of health status changes (159). Common types of effects sizes are 
odds ratio and risk ratio. The standardized mean effect (or Cohen d) is another type of effect 
size and expresses the mean differences between two groups in standard deviation units. 
Effect sizes are mostly used for comparing and integrating results across studies, as in meta-
analyses and for performing power analyses (159). 
 
1.3.7 The placebo effect 
Despite the assumption that placebo treatment is ineffective, there is a wealth of information 
to the contrary. An increased endorphin production in association with placebo analgesia has 
been described (173, 174). Placebo effects in the range of 40-45 % improvement in 
symptoms have been reported in studies monitoring pain (8, 175) and the average strength of 
placebos upon pain on a VAS scale is 2 out of 10 units (176, 177). When patients in a 
clinical trial were treated with “warmth, attention and confidence” the response to a placebo 
increased from 44 % to 62 % (178). Larger effects of placebo interventions are associated 
with physical placebo interventions (like sham acupuncture), patient involved outcomes, 
small trials and trial with the explicit purpose to study placebo (179). In a Cochrane review, 
the placebo effect could be documented only in studies in which the subjects themselves 
reported the outcomes and the improvements in pain were small and could not be clearly 
distinguished from reporting bias (179). Response bias or reporting bias is the tendency for 
patients to report their symptoms in a way they feel are socially acceptable or desirable or the 
way they think the doctor wants (180). In another meta-analysis, placebo had a significant 
effect on pain when measured on continuous scales whereas no effect was seen when the 
outcome was binary (181).  
Thus, placebo interventions in general do not have any clinically important effects but can 
have possible small benefits in studies with continuous subjective and patient-reported 
outcomes and for the treatment of pain (179). In certain settings, placebo interventions can 
influence patient-reported outcomes, especially pain and nausea, though it is difficult to 
distinguish patient reported effect of placebo from biased reporting (179).  
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2 OBJECTIVES 
Previous studies have indicated that pertubation with lignocaine could relieve pain in 
patients with endometriosis (135, 137). This effect was unexpected and was spontaneously 
reported by the patients who did not achieve pregnancy in a fertility study in 2001 (135). 
The effect on pain was further evaluated in a small but randomised study in which different 
concentrations of lignocaine was evaluated. Five of six patients who had been treated with 
the highest concentration of lignocaine (1mg/ml) reported reduced dysmenorrhea (137). 
The purpose of all the present studies was to further evaluate the effect of pertubation with 
Ringer-Lignocaine in women with endometriosis and to find an explanation for a possible 
effect.  
A double-blind, randomised controlled trial was carried out to evaluate the effect of pertubation 
with lignocaine 1mg/ml on dysmenorrhea and quality of life in patients with endometriosis. The 
hypothesis was that pertubation with lignocaine could relieve pain and improve quality of life in 
patients with endometriosis.  
The safety of the method and the pharmacokinetics of lignocaine after pertubation needed 
to be evaluated. Our hypothesis was that the pertubated dosage of 10 mg lignocaine 
hydrochloride reaches the central circulation and gives rise to low systemic levels. 
Pertubation with lignocaine was thought to be safe and without side effects. 
The social support scale on the EHP-30 core questionnaire had previously failed to demonstrate 
responsiveness. The responsiveness should be confirmed in the particular study population and 
the question was raised whether our results from the EHP-30 questionnaire were reliable. The 
primary objective of the fourth study was thus to evaluate the responsiveness and the 
applicability of the EHP-30 questionnaire in our Swedish sample. The hypothesis was that the 
EHP-30 questionnaire was applicable and responsive for change for all dimensions on the EHP-
30 core questionnaire.   
The cytokines in the peritoneal fluid might play a part in the symptoms of endometriosis. 
Lignocaine has anti-inflammatory properties and can decrease cytokine release both in vitro 
and in vivo. With the aim to find an explanation for the clinical effects seen in vivo, the effect 
of lignocaine on cytokine expression and secretion from peritoneal fluid macrophages and 
ectopic endometriotic stromal cells was evaluated in vitro. It was hypothesized that 
lignocaine could attenuate the expression and release of the pro-inflammatory cytokines IL-
6, IL-8 and MCP-1 in cell cultures.  
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The women in study V were recruited at the Department of Gynaecology, Danderyd 
Hospital. Women that were scheduled for surgery for clinical reasons (endometriotic cyst 
enucleation, n=10, laparoscopic sterilisation, n=7) were asked to participate. Information was 
given at the screening visit the day before surgery and all women gave their informed 
consent.  
Samples from 15 women were collected. One patient undergoing laparoscopic sterilisation 
was found to have peritoneal endometriosis. Two of the women with endometriosis never 
got operated and samples were obtained from nine women with endometriosis and six 
healthy controls. One sample from a woman with endometriosis and one from control were 
used for testing the cell culture protocol.  
 
 
3.2.2 Inclusion and exclusion criteria 
The main inclusion criteria in study I-IV were presence of peritoneal or ovarian endometriosis as 
verified by laparoscopy and dysmenorrhea with a pain score of >50 mm on the VAS scale. Main 
exclusion criteria were reduced patency in the Fallopian tubes and intention to achieve 
pregnancy during the forthcoming year. Detailed eligibility criteria are presented in table 1. 
 
Table 1; Inclusion and exclusion criteria study I-IV 
Inclusion criteria Exclusion criteria 
• age > 20 years  
• endometriosis verified by laparoscopy  
• dysmenorrhea or pelvic pain defined as  
a pain score of >50 mm (VAS) 
• normal Fallopian tubes  
• regular menstrual cycles 21-35 days 
• treatment with oral contraceptives (OC)  
ongoing >1 month and continued during  
the trial 
• previous hormonal treatment discontinued  
> 1 month (OC, gestagens) and > 6 months  
      (GnRH agonist)  
• no wish for pregnancy during the study 
• normal Pap smear,  
• negative chlamydia test  
• negative pregnancy test 
• informed consent given and signed 
• continuous treatment with medication  
that may increase risk for infection  
• clinical signs of pelvic inflammatory disease  
• hyper reactivity to local anaesthesia  
• fibroids > 2 cm  
• ongoing treatment with GnRH agonist 
• ongoing continuous treatment with  
high-dose gestagens 
• pregnancy  
• peritubal adhesions  
• occluded Fallopian tubes 
• inability to understand information  
or comply with study procedures 
• participation in a clinical study within  
one year before the present study. 
• any disease or laboratory finding considered  
       of importance by the investigator for not  
       including  the patient 
      
 
 
To be included in study V, the women should be 18 to 45 years of age and either fertile and 
without endometriosis or have visible endometriosis at surgery. The included women should 
also understand written and spoken Swedish. Exclusion criteria were ongoing treatment with 
GnRH or gestagens or on-going pregnancy.   
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3.2.3 Demographics 
The medical history and demographic characteristics of the patients in lignocaine and 
placebo groups were comparable (table 2).  
 
Table 2; Demographics and medical history study I-IV 
 
 Study I, III and IV Study II 
 Placebo (n=18) Lignocaine (n=24) Placebo n=9 Lignocaine n=16 
Parameter Mean (SD) Min-max Mean (SD) Min-max Mean (SD) Min-max Mean (SD) Min-max 
Age years 33.4 (4.4) 26-39 33.08 (5.5) 22-43 32.7 (5.6) 26-40 34.1 (5.8) 25-44 
Weight kg 67.6 (12.2) 50-98 69.5 (11.1) 50-90 69.8 (15.3) 50-98 66.9 (11.2) 50-90 
Height cm 167.4 (8.6) 156-181 164.0 (4.6) 154-172 168.3 (9.9) 156-181 164.3 (4.5) 155-172 
Duration endometriosis1 4.5 (4.46) 0-16 5.5 (4.04) 0-13 3.9 (3.9) 0-12 6.0 (3.8) 1-11 
VAS at inclusion 78.22 (18.62) 43-100 73.58 (19.0) 17-99     
Diastolic BP at inclusion, 74 (7.9) 60-92 77 (9.8) 63-104 76.0 (8.8) 67-92 76.8 (8.5) 63-90 
Systolic BP at inclusion  118 (13.0) 90-148 121 (12.2) 105-156 118.4 (17.9) 100-148 121 (96) 105-140 
Heart rate 68.4 (7.2) 54-80 73.0 (10.0) 58-96 67.3 (5.9) 60-76 72.1 (9.4) 58-91 
 Number   Number  Number   Number  
Smokers 0  4  0  2  
Patients using SSRI 4  3  2  2  
Patients using analgesics 18  24  9  16  
Paracetamol 12  14  2  9  
NSAIDs 13  22  6  19  
Codeine 6  5  4  4  
Tramadol 1  2  1  0  
Dextropropoxyphene 1  4  0  2  
Other opioids 2  3  2  0  
Oral contraceptives  3  2  3  2  
Intrauterine device 0  1  0  1  
Levothyroxine 2  1  2  1  
Corpus luteum cyst 3  1  2  1  
Endometrioma 0  2  0  1  
1. Years since diagnostic laparoscopy 
   25 
A total of 17 patients were included in study V, of which eleven had endometriosis and six were 
healthy controls. One patient undergoing laparoscopic sterilisation was found to have peritoneal 
endometriosis and was therefore considered to have endometriosis. The mean age was 34.7 years 
for women with endometriosis and 41.1 years for the healthy controls. Two women were on 
contraceptive pills (one healthy, one endometriosis), one had been treated with progestin 16 days 
earlier (healthy) and one had a hormonal intrauterine device (endometriosis). Two women were 
treated with SSRI (both healthy).  
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4 METHODS 
 
4.1 STUDY DESIGN 
Study I and III were both randomised, double-blinded and controlled clinical studies. The effect 
of pertubation with lignocaine on pain (study I) and quality of life (study III) was evaluated. The 
patients were sequentially randomised to receive study treatment (pertubation with lignocaine 
1mg/ml in Ringer solution) or placebo (pertubation with Ringer solution). Three treatments were 
to be given pre-ovulatory on cycle day 6-12 in three sequential menstrual cycles. The effect was 
evaluated with two questionnaires concerning pain and health related quality of life. 
Study II and IV were both prospective observational studies. In study II the concentration of 
lignocaine in serum after pertubation was measured and presented. In study IV the 
responsiveness of the EHP-30 questionnaire was evaluated. 
Study V was an experimental in vitro study on human cells. 
 
4.2 POWER CALCULATION  
The primary outcome in the randomised study was the effect on pain and a power analysis 
was conducted for this outcome. The power calculation was based on a preceding study in 
which five of six patients were improved after pertubation with lignocaine 1.0 mg/ml (137). 
In the power analysis using the Chi square test at 80 % power, it was assumed that 60% of 
the subjects given the study treatment and 20% in the control group would improve. To 
achieve a statistical significance (p<0.05, using Fisher’s exact two-sided test), 20 subjects 
had to be randomised in the treatment group and 15 subjects in the control group.  
A 4:3 treatment/placebo rate was used to gain more safety data and to encourage women to 
participate since the chance of active treatment compared to placebo was higher.  
A power calculation was not made for the secondary outcome quality of life since no 
preliminary results for the effect on quality of life were available.  
 
 
4.3 PROCEDURES (STUDY I-IV) 
Patients included in study I-IV had four visits of which the first was a screening visit and the 
other three were treatment visits. The treatments were given over three sequential menstrual 
cycles. Data from a previous study had given indications that the effect on dysmenorrhea 
increased after repeated treatments (135), hence it was decided to use three treatments. 
 
4.3.1 First visit 
At the first visit, the study patients were scrutinised concerning the inclusion and exclusion 
criteria. A physical examination including blood pressure, gynaecological examination 
including wet smear and a vaginal ultrasound were performed. Chlamydia and pregnancy 
tests were taken and bacterial vaginosis, if present, was treated. The subjects should have had 
a normal Pap smear taken within the previous three years and if not a new smear was carried 
out. Demographic data, concomitant medication and medical history were recorded. The 
patency was considered normal if the preceding laparoscopy revealed normal Fallopian tubes 
anatomy. In five patients, three in the placebo group and two in the lignocaine group, 
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information concerning patency of the Fallopian tubes was missing in the patient records or 
history, and therefore hystero salpingo contrast sonography was performed prior to study 
entry. 
 
4.3.2 Second, third and fourth visit 
At the second visit, the patients were randomised sequentially as they were eligible. At the 
treatment visits, any changes in concomitant medication, medical status or presence of any 
adverse events (AE) since the preceding visit were recorded. Before each treatment a 
pregnancy test and a gynaecological examination including wet smear were performed to 
confirm the absence of bacterial vaginosis or signs of pelvic inflammatory disease. The 
pertubations were carried out on menstrual cycle day 6-12 since some patients were in 
natural cycles and could possibly get pregnant. A thin plastic catheter (PBN-Medicals, 
Stenløse, Denmark) was inserted in the cervical canal or in the distal part of the uterine 
cavity and a small intraluminal rubber balloon on the catheter was inflated with saline to 
prevent retrograde leakage. Blood pressure and heart rate were measured and recorded 
before and five minutes after the treatment. 10 ml of solution was infused through the uterine 
cavity and pertubated into the peritoneal cavity (figure 2). The solution was infused with 
vaginal ultrasound supervision during approximately 5 minutes and the fluid could be seen in 
the pouch of Douglas after treatment. The patients did not receive lignocaine by any other 
route during the study.  
 
Figure 2; The pertubation process 
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4.3.3 Randomisation 
The patients were randomised sequentially as they were eligible. Solutions for pertubation 
were produced and released in a double-blinded manner (APL/Apoteket Production & 
Laboratories, Box 6124, SE 906 04 Umeå, Sweden). The double-blinded study solutions 
were delivered to the sites in blocks of treatments for seven patients: three placebo and four 
study treatment kits. In total six blocks were completely used. After randomisation of a 
patient, each site assigned the patient to the next available treatment kit in the on-going 
block. The randomisation list remained at APL until a clean file was declared. 
 
 
4.3.4 Serum sampling (study II) 
At one occasion, serum samples were collected and for practical reasons at only one of the study 
centres (Danderyd hospital). All patients that accepted the serum sampling at this centre were 
included in study II (n=25). A peripheral venous catheter was inserted in vena brachialis before the 
treatment and a 10 ml blood sample was collected at 0, 5, 15 and 30 minutes after pertubation i.e. 
totally 40 ml. The samples were centrifuged, the serum was stored at –70 degrees Celsius and later 
analysed in one batch for the concentration of lignocaine. The samples were collected from April 
2007 until Nov 2008 and the analyses were made in April 2009. Since the study was blinded, tests 
were taken on both patients who received lignocaine (n=16) as well as placebo (n=9).  
The concentration of lignocaine in serum was determined with a LCMS-SIM method 
(OncoTargeting AB. Rapsgatan 7, 754 50 UPPSALA). The smallest observed peak with this 
method was 6 nM (1.4 ng/ml), the detection limit was 18 nM (4.2 ng/ml) and the limit of 
quantification was 60 nM (14.1 ng/ml).  
 
4.3.5 Per protocol and Intention to Treat (study I and III) 
The intention to treat (ITT) population consists of all women randomised. Previous studies 
had given indications that the effect on dysmenorrhea increased after repeated treatments 
(135) and in the present study three pertubations during a maximum of five menstrual cycles 
was considered a successful treatment, thus fulfilling the prerequisites to be included in the 
Per Protocol (PP) population.  
 
 
4.4 FOLLOW UP AND QUESTIONNAIRES  
4.4.1 Pain and dysmenorrhea (I, III and IV) 
The effect on dysmenorrhea in study I was evaluated with a pain questionnaire including a 
VAS scale, initially filled out at the menstruation before the first treatment, i.e. baseline. 
Thereafter the pain questionnaires were completed during the 2nd, 3rd and 4th period, i.e. 
after every treatment. The final follow-up took place after the 7th, 10th and 13th menstrual 
period, i.e. 6, 9 and 12 months after initial treatment. The maximum pain on the VAS scale 
during every menstrual period was recorded and a decrease on the VAS scale of ≥50% from 
baseline was defined as a success. Initially, also a decrease on the VAS scale of >40 mm 
from baseline was defined as a success. This outcome was however deleted from the 
published version due to comments from reviewers. Obtaining a VAS <20mm was also 
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evaluated and considered a secondary end point since it indicate a low pain level. The change 
on the VAS scale was the primary outcome in the first study. 
 
The pain questionnaire used was a revised version of the Biberoglu and Behrman scale 
(1981) including the three symptoms; dysmenorrhea, dyspareunia and chronic pelvic pain. 
The function because of pain was evaluated by patients on the categorical scale (0-3), 
ranging from no pain to bedridden for the major part of the day. The dysmenorrhea was 
evaluated on menstrual cycle day 1, 3 and 5. The sum of the pain scores from the categorical 
scales (0-12) were compared between the different time points and a decrease by ≥2 from 
baseline was defined as a treatment success.  
The participating patients in study I were also asked to report the use of rescue medication, 
their need to be on sick leave and to estimate any changes in their overall pain level,  all of 
which were secondary outcomes.  
The time point for primary efficacy evaluation was after the third and last pertubation that 
corresponded to the fourth menstruation approximately three months after the initial treatment. 
The secondary time points for primary efficacy evaluation were after 6, 9, and 12 months 
respectively.  
In addition, the patients were asked to estimate changes in their overall pain level during and 
between periods by answering the response categories “much better”, “somewhat better”, “about 
the same”, “somewhat worse” or “much worse”. This corresponds to the global question on the 
general quality of life questionnaire SF-36 (appendix 9.4) and can be used to examine the 
responsiveness of an instrument (166) and to calculate the minimal important difference (170).  
The estimated change in pain intensity and the results from the EHP-30 questionnaires were used 
to evaluate the responsiveness of the EHP-30 questionnaire in study IV. The patients in the 
lignocaine and the placebo groups were in study IV analysed all together and were grouped 
according to their own estimation of change in pain intensity. The patients that estimated their 
pain to be “somewhat better” during and/or between periods were classified as better (n=17) and 
the patients that felt “somewhat worse” or “much worse” during and/or between periods were 
classified as worse (n=8). Patients that estimated their pain to be “about the same” both during 
and between periods were classified as “same” (n=6) and the two patients that became “much 
better” both during and between periods were classified as pain free. One patient was removed 
from analysis since she could not be classified according to the above definition. She became 
pain free between periods whereas the pain during periods became worse. 
The patient´s estimation of change in pain intensity was also used in study IV and III to calculate 
the minimal important differences (MID) on the EHP-30 questionnaire. The MID for the scores 
on the EHP-30 in our material correlate to the mean change from baseline to follow up after six 
months for patients who felt “somewhat better” considering pain intensity after six months and 
excluding the ones that became pain-free (Appendix 9.1. Pain questionnaire). 
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4.4.2 Quality of life (study III and IV) 
The effect on QOL was evaluated with a Swedish translation of the EHP-30 questionnaire 
(Pharmacia UpJohn, 2001) and were initially filled out before the first treatment i.e. baseline. 
The follow-up took place after the 7th and 13th menstrual period, i.e. six and 12 months after 
initial treatment. The patients received the treatments before the 4th period and no treatments 
were given the subsequent two periods preceding the collection of the EHP-30 questionnaire 
after six months. All dimensions and items on the core questionnaire were collected. On the 
modular questionnaire the score concerning sexual intercourse (five items) were included. 
If one or more items were missing from any dimension on the core and modular questionnaire, a 
scale score could not be calculated for that individual (168). Only the complete scores are 
presented for the different dimensions giving different number of patients in various dimensions. 
Furthermore, if any item was missing in any dimension at baseline, this specific score was 
withdrawn from further analysis concerning this specific dimension. All scores on the different 
dimensions on the EHP-30 are ranging from 0 (best health status) to 100 (worst health status). A 
decrease on a score scale (i.e. negative change) at follow up implies that the patient has 
improved considering this dimension on quality of life (Appendix 9.2.). 
 
 
 
 
 
 
 
 
 
 
 
4.5 PROCEDURES STUDY V 
 
4.5.1 Study material 
4.5.1.1 Endometriotic cyst capsules (ECC) 
From patients with endometriosis (n=7), a part of the endometriotic cyst capsule (ECC) was 
obtained after enucleation. Five ECC were collected from women in the proliferative phase and 
two in the secretory phase of the menstrual cycle.  
4.5.1.2 Peritoneal fluid (PF) 
For isolation of monocytes/macrophages, peritoneal fluid (PF) was collected from all 
participating women. The peritoneal fluids from the patients with endometriosis were obtained in 
the secretory phase (n=2) and in proliferative phase (n=3), respectively. The peritoneal fluids 
from controls were collected during the secretory phase (n=3), the proliferative phase (n=1) and 
one from an amenorrhoic woman who used oral contraceptives.  
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coated with 0.2% gelatine (Sigma) The cells were cultured until confluence and thereafter 
harvested and stored frozen in liquid nitrogen.  
The thawed cells were used for treatment in the second passage. The ECC cells were cultured in 
6-well plates for RNA determination and ELISA analysis. When the cells were confluent, they 
were treated with lignocaine at a final concentration of 0.1 mg/ml or 1.0 mg/ml. The treatments 
were performed in triplicates and the cells were cultured for 24h and 48h. For ELISA, the culture 
medium was stored in -70°C until assay. The cells were harvested using lysis buffer with β-
mercapto ethanol (Qiagen) and stored in -70°C until assay.  
 
4.5.2.2 Cells from the peritoneal fluid 
Peritoneal fluid (PF) was collected aseptically before initiation of surgical procedures. Teflon 
catheters (tetrafluoro ethylene, diameter 1.7 mm; Optinova, Godby, Finland) and bottles of 
Teflon (Nalgene, Brochester, NY, USA) were used to prevent macrophages to adhere to the 
surfaces. Heparin (100 IE/ml) was supplemented to the PF to an estimated concentration of 10 
IE/ml to avoid coagulation. The PF samples were transported to the laboratory at Uppsala 
University Hospital and were isolated within 3 hours. 
The PFs were centrifuged at 2000 x g for 5 minutes and the cells were then re-suspended in 
RPMI 1640 medium (Life technologies). Mononuclear cells were thereafter isolated by using 
gradient centrifugation at 2000 x g for 15 min (Ficoll-Paque Plus, GE Healthcare Biosciences 
AB). After that, the cells were suspended in RPMI 1640, centrifuged at 2000 x g for 5 minutes 
and subsequently re-suspended in medium (RPMI 1640 supplemented with 1% L-glutamate 
(Life technologies), 1% Penicillin Streptomycin (Life technologies) and 1% foetal calf serum 
(Life technologies). The cells were dispensed and allowed to adhere in two wells in a 6 well 
plate for 45 minutes in an incubator at 5% CO2, 37°C. Non-adherent cells were removed by 
washing three times with RPMI and the adherent cells were then cultured for 24 h in medium 
(RPMI 1640 supplemented with 1% L-glutamate (Life technologies), 1% Penicillin 
Streptomycin (Life technologies) and 1% foetal calf serum (Life technologies) with and without 
lignocaine at a final concentration of 0,1mg/ml. After 24 h, the supernatants were collected and 
kept at -70°C until ELISA assay. Lysis buffer (Quiagen) was added to adherent cells, which were 
thereafter stored at -70°C. 
 
4.5.3 Proliferation and viability assay on cells from ECC 
For determination of viability and proliferation, the ECC cells were cultured in 96-well 
plates to confluence and thereafter treated with lignocaine or control medium. Lignocaine 
treatment was performed at five different concentrations: 0.05 mg/ml, 0.1 mg/ml, 0.5 mg/ml, 
1 mg/ml, and 1.5 mg/ml. Two different exposure times, 24h and 48 hours were used. Each 
treatment was performed in ten wells.  
Cell proliferation is a measurement of the number of cells that are dividing in a culture and 
were measured using a BrDU (5-bromo-2-deoxyuridine) ELISA. Metabolic activity can be 
assayed as an indication of cell viability and the WST-1 assay (the ability of viable cells to 
cleave tetrazolium salts) was used for this measurement. The viability and proliferation 
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assays were carried out after lignocaine exposure according to the instructions from the 
manufacturer (Roche Diagnostics Scandinavia AB, Bromma, Sweden).    
 
4.5.4 RNA isolation, cDNA synthesis and RT-PCR  
RNA was isolated from lysed cells (cells from ECC and PF macrophages) using RNeasy 
Mini kit from Qiagen according to the instructions from the manufacturer. RNA 
concentration and purity was determined using NanoDrop. The quality of total RNA was 
determined using Agilent 2100 Bioanalyzer (Agilent Technologies, Sweden AB, Kista, 
Sweden). The RIN (RNA-integrity number) values differed between 2.7 and 9.4 for the RNA 
from PF macrophages and were 9.9-10 for RNA from ECC cells. All RNA sample were used 
for QPCR. 
Synthesis of cDNA was performed by using SuperScript™ III Reverse Transcriptase First-
Strand cDNA Synthesis (RT) (Invitrogen).  
Quantitative PCR (QPCR) of cDNA was performed using TaqMan Real-time PCR (Applied 
Biosystems) for the cytokines IL-6, IL-8 and MCP-1, using 18S as housekeeping gene. The 
primers used were for IL-6 Hs00985639, for IL-8 Hs00174103 and for MCP-1/CCL2 Hs 
00234140, all from TaqMan Gene Expression, Applied Biosystems.  
 
4.5.4.1 The Real time-PCR principle 
TaqMan reagents use a fluorogenic probe to detect a specific PCR product as it accumulates 
during the PCR. With each PCR cycle, more reporter dye molecules are cleaved from their 
respective probes during primer extension, resulting in an increase of fluorescence intensity. This 
fluorescence intensity is proportional to the quantity of produced amplicon. The higher the 
starting copy number of the nucleic acid target the earlier a significant increase in fluorescence is 
observed. The cycle threshold (CT) is the number of cycles needed to reach the particular 
threshold fluorescence signal level (182). An internal reference gene (whose expression should 
be constant) can be used to compare samples and thereby compensate for differences in the 
amount of biological material in the tested samples.  
We used 18S as internal reference for comparative quantification and calculated the relative gene 
expression using the ΔΔCT method (182).  
For ECC cells also the standard curve method was used (to calculate the exact amount of 
RNA) but only the relative expressions are presented due to large spread in the RNA 
concentrations between samples. 
The standard curve method could not be used for the macrophages due to lower amount of 
RNA and only relative expression in relation to 18S was calculated and presented. 
 
4.5.5 ELISA on cell culture medium 
Concentration of the cytokines MCP-1, IL-6 and IL-8 in culture media from ECC cells and 
PF macrophages were analysed using an ELISA according to the instructions from the 
manufacturer (Human MCP-1 ELISA, Human IL-6 ELISA and Human IL-8/CXCL8 
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ELISA, Biosensis). The concentrations of MCP-1, IL-6 and IL-8 were related to the total 
RNA concentration in each sample. 
 
4.5.5.1 The ELISA principle  
The used ELISAs were sandwich ELISAs. The plates were precoated with antibodies specific for 
the cytokine that was to be detected. Samples and standards is added and then a secondary 
antibody specific for the cytokine. After washing, an enzyme complex is added which binds to 
the secondary antibody and peroxidase substrate is then added to induce a coloured reaction 
product. The intensity of the colour is proportional to the concentration of the cytokine in the 
sample.  
 
4.5.6 Cell staining  
In order to classify the ECC cells as of epithelial or stromal origin a cytochemical staining 
was performed. The ECC cells from five women were cultured on cover glass. The cells 
were fixed in paraformaldehyde, 4%, for 15 minutes, washed with PBS x3, permeabilised in 
cold methanol for 5-10 minutes at -20ºC and again washed in PBS x3. Thereafter, the cells 
were incubated with mouse anti-human cytokeratine (Clone AE1/AE3 DAKO Corporation) 
or rabbit anti-human vimentin (ab16700, Abcam) at 4°C overnight.  After that, a fluorescent 
secondary antibody (Fluorescein anti mouse IgG or DyLight 594 anti-rabbit, Vector 
laboratories Inc, CA, USA) was added and the cells were incubated for 30 min at room 
temperature. The staining was evaluated using a fluorescence microscope (Zeiss, Axio 
Observer.Z1). 
 
4.6 STATISTICS 
For statistical analysis, Statsoft Statistica 10, Statsoft Statistica 12 and Microsoft Excel 2007 
were used. Mostly non-parametric tests have been used due to ordinal scale variables and the 
relative small sample sizes.  
In study I, the results were dichotomised and the success rate between the treatment and the 
placebo groups at different time points was compared using Fisher’s exact test. The 95% 
confidence interval was requested by reviewers and considered an exploratory analysis since the 
study population was too small to assume normal distribution. In this thesis, also the change on 
the VAS scale from baseline to different follow up time points are compared between groups 
with Mann Whitney U test as an exploratory statistics. 
In study II, only descriptive statistics were used. 
In study III, the changes in the different dimensions on the EHP-30, from baseline to the follow 
up time points were compared between the treatment and the placebo groups with Mann 
Whitney U test (MWU test). Furthermore, the changes in the EHP-30 scores in the lignocaine 
and the placebo groups respectively were compared with the proposed MID and the proportion 
of patients improving more than the MID are reported. The purpose was to evaluate whether the 
improvement in quality of life could be perceived by the patients or not. The change in social 
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support scale after six months for those who improved /not improved >50% on VAS scale after 
four months was compared with MWU-test.  
In study IV, the responsiveness to change for the EHP-30 questionnaire was evaluated with 
effect sizes and significance of change (paired t-test) in the improved and the stable groups. 
All the patients that were better or pain free (improved group) were compared with all the 
patients that felt the same or worse (stable group) independent of treatment group (lignocaine 
or placebo). The changes in EHP-30 scores between the improved and the stable groups were 
compared with independent student t-test.  
In addition to the above parametric tests, complementary statistical analyses with non-
parametric tests have been performed in this thesis. Mann Whitney U test was used for the 
differences in change between the improved and the stable groups and Wilcoxon signed 
ranks test for matched pairs for significance of change within groups.  
The effect size was calculated by dividing mean difference with pooled SD  i.e. Cohen d 
(156). Negative effect sizes correlates to improved quality of life in our material since a 
lower score indicate better Quality of Life.  
The MIDs for scores on EHP-30 correlate to the mean change for patients who felt 
“somewhat better” (170). A negative value on the mean change means the EHP-30 score is 
lower at the follow up and thus that the patients are improved considering their quality of 
life.  
 
In study V, Wilcoxon signed ranks test for matched pairs was used for data on cell viability 
and proliferation. The different concentrations of lignocaine were compared with the control 
(0 mg/ml) as well as with the next higher concentration at 24 and 48h respectively.  
The relative gene expression and protein synthesis of MCP-1, IL-6 and IL-8 for cells treated 
with lignocaine were compared to untreated cells using Wilcoxon matched paired test. 
Relative expression was calculated using the ΔΔCT method (Delta-Delta-Cycle Threshold-
method) (182) and the control were set to 1 since 20=1. The means of triplicate from each 
sample were used. 
Differences between cell types were compared using Mann Whitney U test.  
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It was not possible to give the three treatments consistently during three consecutive cycles 
for different reasons such as bacterial vaginosis and because study patients were occasionally 
on vacation. However, the majority of the patients obtained their treatments over a period of 
three months (n=29) or within five months (n=38).  
 
5.1.1 Primary end-point 
The time point for primary efficacy evaluation was after the third and last pertubation that 
corresponded to the fourth menstruation approximately three months after the initial treatment. 
For the ITT analysis, 10 of 24 patients (41.7%) in the treatment group versus 3 of 18 patients 
(16.7%) in the control group fulfilled the criteria for success as having a decrease of ≥50% on 
the VAS scale (p=0.10, 95 % CI -7.26 to 36.2%). In the PP analysis, 9 of 20 (45.0 %) compared 
to 1 of 14 (7.1%) had a decrease of ≥50% on the VAS scale (p=0.024, 95 % CI -2.61 to 44.8%). 
With other definitions of success, i.e. a decrease on the VAS scale of ≥40mm or VAS below 
20mm at a specific time point, similar results were obtained (table 3). 
 
Table 3; Success rate on VAS scale at primary end-point 
Definition of success population Placebo 
Success rate 
Lignocaine 
Success rate 
p-value 
Fisher´s exact 
Decrease in VAS ≥ 50% ITT 3/18  10/24   0.10 
PP 1/14    9/20     0.024 
Decrease in VAS ≥40mm ITT 2/18     8/24     0.15 
PP 1/14     8/20     0.050 
VAS ≤ 20mm  ITT 2/18     7/24   0.26 
PP 0/14  6/20 0.031 
 
In the PP population, nine of the patients in the lignocaine group (n=20) and one in the placebo 
group (n=14) improved by ≥50% on the VAS scale from baseline to the first menstruation after 
the third treatment. In the lignocaine group, three of these nine patients were improved by ≥50% 
on the VAS scale after the first treatment and five after the second treatment. Three months after 
the third treatment, four of these nine patients in the lignocaine group still fulfilled the criterion 
of an improvement of ≥50% on the VAS scale from base line. This improvement persisted for 
six months after the last treatment for two patients and for nine months for four patients. The 
only patient in the placebo group, who improved by ≥50% after the third treatment, had not 
improved after the first or second. She was still improved three months after the third treatment, 
but thereafter her pain level was back at baseline (table 4). Also in this extended analysis of the 
improved patients in the PP population, the results were equal and independent of the definition 
of success.  
Six patients in the lignocaine group achieved the secondary end point <20 mm on the VAS-scale 
compared to none in the placebo group (p= 0.031). Five of the nine subjects (56%) who 
responded to the treatment in the lignocaine group had no pain symptoms (VAS ≤4 mm). No 
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patient in the placebo group reached VAS of ≤10 mm at the time point for primary efficacy 
evaluation.  
 
Table 4; Successful treatments in the PP population after three pertubations 
 
 
5.1.2 Secondary end-points 
When analysing the sum of scores from the categorical scales during menstruation between 
baseline and the primary time-point after the third treatment, there were no significant 
differences between the groups.  
The participating patients were asked to estimate any changes in their overall pain level, and 
13 of the 24 patients in the lignocaine group and 11 of 18 in the placebo group reported 
reduced dysmenorrhea after the third treatment. Four patients in the lignocaine group 
experienced no dysmenorrhea at all. The change in the use of analgesics from baseline to 
primary time-point was comparable between the groups, and no significant changes were 
found. Only half of the study population reported a need to be on sick leave. The change in 
work capacity was similar between the groups.  
Blood pressure and heart frequency recorded before pertubation were normal and did not change 
in either the lignocaine or the placebo group following treatment. 
 
The secondary time points for primary efficacy evaluation were after 6, 9, and 12 months 
respectively.  No significant differences in success rate were found on the VAS scale 
between the treatment group and the placebo group either in the ITT or in the PP population 
(table 5). Neither were there any differences between groups when analysing the sum of 
scores from the categorical scales at the secondary end-points.  
 
               Time point     
 
                      
After the 
first 
treatment 
After the 
second 
treatment 
Success, first 
menstrual 
period after the 
third treatment 
3rd menstrual 
period after the 
third treatment 
6th menstrual 
period after the 
third treatment 
9th menstrual 
period after 
the third 
treatment Definition of success 
Improved 
≥40 mm on 
VAS scale 
from baseline  
Lignocaine n=8 3 6 8 5 3 4 
Placebo n=1 0 0 1 1 0 0 
Improved 
≥50 % on 
VAS scale 
from baseline 
Lignocaine n=9 3 5 9 4 2 4 
Placebo n=1 0 0 1 1 0 0 
VAS  ≤20 
mm at 
specific time 
point 
Lignocaine n=6 2 2 6 3 2 2 
Placebo n=0 0 0 0 0 0 0 
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Table 5; Success rate on VAS scale at secondary end-points 
  After six months After nine months After twelve months
Definition of success Population Lignocaine Placebo Lignocaine Placebo  Lignocaine Placebo 
Decrease in  
VAS ≥ 50% 
ITT 4/17 4/14 2/14 3/12 4/14 2/9 
PP 4/16 3/11 2/14 1/9 4/13 1/7 
Decrease in  
VAS ≥40mm 
ITT 5/17 5/14 3/14 3/12 4/14 0/9 
PP 5/16 3/11 3/14 1/9 4/13 0/7 
 
 
Additional statistics have been made in this thesis using the VAS scale as a continuous variable. 
The improvement on the VAS scale was significantly larger in the lignocaine group nine months 
after the third pertubation compared to the placebo group and the difference was significant with 
Mann Whitney U-test (p=0.04). There were no significant differences at the other time points 
and the spread between patients were large (table 6). 
 
Table 6; Change on VAS scale at all time points 
 
 
5.2 STUDY II: 
A total of 97 serum samples were collected from 25 patients of whom 16 had been treated with 
lignocaine hydrochloride 10 mg and nine with placebo (Ringer Acetate). Due to problems with 
the peripheral venous catheter, samples could not be taken from one patient in the lignocaine 
group after 0 and 30 minute and also a 30 minutes sample is missing in the placebo group.  
All patients were healthy and without cardiovascular or hepatic disease that might affect the 
pharmacokinetics of lignocaine. Baseline data and medication for patients included in the serum 
screening can be seen at 3.2.3. Demographics. 
Time-point Population Placebo 
Median(IQR) 
Min-max 
Lignocaine 
Median(IQR) 
Min-max 
p-value 
MWU-test 
Four months ITT 23.5 (11.25-31.75) 
(-27)-71 
30 (8.5-55) 
(-8)-88 
0.52 
PP 23.5 (11.25-31.75) 
(-27)-71 
34.5 (8,75-58,75) 
(-8)-88 
0.29 
Six months ITT 14 (-4-40) 
-29-56 
11.5 (2-27.5) 
(-26)-91 
0.96 
PP 11.5 (-3.5-39) 
(-29)-56 
18 (3-44) 
(-26)-91 
0.84 
Nine months  ITT 8 (0-29) 
(-28)-51 
10 (0-38) 
(-19)-64 
0.62 
PP 6 (0-17.25) 
(-7)-51 
21 (3-40.5) 
(-13)-64 
0.29 
Twelve months ITT 1 (-4-7) 
(-31)-35 
19 (4-38.5) 
(-7)-72 
0.04 
PP 4 (-4-9.5) 
(-31)-35 
19.5 (6-42.25) 
(-3)-72 
0.04 
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In total, 166 gynaecological examinations were carried out during the study, 42 of which 
were screening visits and 124 were treatment visits. There were no adverse events related to 
the treatment with lignocaine. Blood pressure and heart frequency recorded before 
pertubation were normal and did not change in either the lignocaine or the placebo group 
following treatment. A mild discomfort was experienced during the pertubation process at 11 
of 124 treatments. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5.3 STUDY III 
The change in quality of life was evaluated after pertubation with lignocaine (n=24) or 
placebo (n=18).  
The groups were well matched in all demographic parameters and the pain intensity on the VAS 
scale was comparable. Two patients in each group initially reported a pain level on the VAS 
scale of >50mm but later when the baseline questionnaire where analysed proved not to fulfil 
this inclusion criterion. The groups had similar usage of concomitant medications such as 
selective serotonin reuptake inhibitors (SSRI), and OC (table 2). All patients used analgesics 
when needed.  
The ITT population consisted of 42 patients. The results were similar in the PP and ITT 
population and therefore only the results from the ITT population are presented.   
Only the complete scores are presented for the different dimensions giving different number of 
patients in various dimensions. One patient did not fill in the EHP-30 at baseline and was 
excluded from further analyses. Flow chart of participants and follow up can be seen in figure 6.  
All scores on the different dimensions on the EHP-30 are ranging from 0 (best health status) to 
100 (worst health status). A decrease on a score scale (i.e. negative change) at follow up implies 
that the patient has improved considering this dimension on quality of life.  
The baseline quality of life was similar between the lignocaine and the placebo groups and there 
were no significant differences with MWU test (table 8).  
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After six months from the first treatment (i.e. two-three months after the last treatment) there 
was a significant difference between the lignocaine and the placebo groups on the EHP-30 
questionnaire for the dimension social support. There were no differences between the 
groups for the other dimensions after six months (table 9). After twelve months there were 
no differences between the lignocaine and the placebo groups concerning the change in 
EHP-30 in any dimension, hence the significant effect seen at six months regarding social 
support disappeared (table 9).  
 
 
Table 9; Change in the EHP-30 questionnaire 
EHP-30  
dimension 
Change after six months Change after twelve months 
Lignocaine Placebo MWU test Lignocaine Placebo MWU test  
Median 
IQR 
Median 
IQR 
p-value Median 
IQR 
Median 
IQR 
p-value 
Pain -13.6 
(-27.3)-2.3 
n=20 
-11.4 
(-22.7)-(-2.3)
n=15 
0.99 -8.0 
(-29.5)-2.3 
n=14 
-11.4 
(-20.5)-(-4.5) 
n=9 
0.69 
Control and  
Powerlessness 
-8.3 
(-33.3)-2.1 
n=20 
-6.3 
(-35.4)-2.1 
n=16 
0.84 -12.5 
(-37.5)-(-8.3)
n=13 
-20.8 
(-41.7)-0 
n=10 
0.74 
Emotional  
well-being 
-4.2 
(-37.5)-4.17 
n=18 
-12.5 
(-20.8)-6.25 
n=16 
0.99 -20.8 
(-37.5)-0 
n=12 
-12.5 
(-25.0)-4.17 
n=10 
0.63 
Social support -18.8 
(-31.25)-0 
n=19 
-6.3 
(-12.5)-6.25 
n=16 
0.034 -12.5 
(-37.5)-0 
n=15 
-6.3 
(-31.25)-12.5 
n=10 
0.50 
Self image -8.3 
(-16.7)-0 
n=19 
0.0 
(-16.67)-8.33
n=16 
0.24 -8.3 
(-16.7)-0 
n=15 
0.0 
(-16.7)-0 
n=10 
0.57 
Sexual intercourse -10.0 
(-25.0)-10.0 
n=15 
5.0 
(-10)-5 
n=14 
0.24 -7.5 
(-15.0)-5 
n=12 
-7.5 
(-20.0)-7.50 
n=8 
0.97 
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When comparing the mean changes on the EHP-30 questionnaire after six and 12 months with 
the minimal important differences (MID), the levels were surpassed for more dimensions in the 
lignocaine group compared to the placebo group (table 10). The fact that the mean change 
exceeds the MID does not mean that all patients are improved and the proportion of patients 
improving above the MID can be seen in table 10. A significant difference between lignocaine 
and placebo groups were found for the social support scale when comparing the proportion of 
patients improving more than the MID (Fisher exact test, p=0.036) 
 
Table 10; Mean change on the EHP-30 and proportion improved above the MID  
 
 
 
EHP-30 
dimensions 
 
 
 
 
 
MID 
Mean(SD) 
After six months After twelve months 
Lignocaine Placebo Lignocaine Placebo 
Mean(SD) 
Proportion 
improved 
> MID 
Mean(SD) 
Proportion 
improved 
> MID 
Mean(SD) 
Proportion 
improved 
> MID 
Mean(SD) 
Proportion 
improved 
> MID 
Pain  -19.9 (18.8)  
n=17 
-14.4(22.5) 
6/20 
-12.0(15.0) 
4/15 
-14.6(22.0) 
4/14 
-13.4(14.8) 
3/9 
Control and powerlessness -25.7 (25.9)  
n=17 
-18.5(27.2) 
8/20 
-16.9 (25.6) 
5/16 
-26.0(24.5) 
6/13 
-20.8(21.8) 
3/10 
Emotional well-being -13.9 (21.4)  
n=15 
-10.0(25.8) 
5/18 
-8.1(22.7) 
8/16 
-19.8(24.3) 
7/12 
-15.4(25.1) 
5/10 
Social support -12.9 (18.0)  
n=17 
-18.8  (20.3) 
11/19 
-3.1(15.0) 
3/16 
-17.9(22.4) 
7/15 
-10.63(31.0) 
4/10 
Self image -6.9 (15.6)  
n=17 
-7.9 (17.0) 
10/19 
-0.52(13.8) 
6/16 
-8.9 (12.4) 
9/15 
-5.8(18.0) 
4/10 
Sexual intercourse -4.5 (27.8) 
n= 14 
-8.2 (25.4) 
8/15 
-0.0(21.1) 
5/14 
-5.6 (22.6) 
9/12 
-5.0(17.7) 
5/8 
 
 
To evaluate the authenticity of the results seen on social support scale some additional 
calculations were done. The relation between the change in pain level immediately after three 
pertubations and the effect on social support scale two months later was investigated with data 
from study I. Those who improved on the VAS scale >50% after four months (lignocaine n=10, 
placebo n=3) had significantly better score on social support after six months (p=0.005, MWU-
test) compared to those who did not improve on the VAS scale (lignocaine n=9, placebo n=13). 
The difference concerning the change on the social support scale between these groups was 
however not significant (p=0.32, MWU-test). The baseline VAS did not differ significantly 
between those groups (p=0.43, MWU-test) but there was a tendency to better social support scale 
(p=0.09, MWU-test) at the baseline in the improved group. 
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5.3.1 Study I-III withdrawals 
Five patients became pregnant during the study and were withdrawn from further evaluation. 
Two patients in the lignocaine group achieved spontaneous pregnancy after the first and third 
pertubation respectively. Three patients in the placebo group became pregnant after IVF. The 
pregnancies were normal. One malformation was registered in the placebo group after IVF 
treatment and the other children were healthy.  
Two patients in the lignocaine group were withdrawn because of endometriomas >25 mm 
diagnosed one and four months after third treatment, respectively. They were surgically 
treated and withdrawn from further evaluation. Another patient in the lignocaine group 
discontinued five days after the third treatment because of such painful endometriosis that 
continuous OC had to be initiated. In the placebo group, three patients were withdrawn 
during the study due to escalating pain and need for other therapies such as high doses of 
gestagens or GnRH agonists.  
 
 
 
 
 
 
 
 
 
 
 
 
5.4 STUDY IV 
In total, 103 EHP-30 questionnaires were collected at different time-points, 41 at baseline, 36 
after six months and 26 after 12 months. The demographic of the whole study population 
was as follows: the mean age was 33.2 (±5.1) years (minimum 22 and maximum 43 years) 
and the mean duration of endometriosis was 4.95 (±4.2) years (minimum 0 and maximum 16 
years). Of the included patients 65% were nulliparous, 19% had delivered once and 14 % 
were multiparous with at least two children 
The questionnaires collected after six months were used for the responsiveness analyses whereas 
the data completeness analysis also includes the questionnaires collected after twelve months.  
Data completeness for the core scales was good. For the modular score sexual intercourse, 
data were complete in all 103 questionnaires but 11/103 (11%) could not be analysed since 
patients reported they did not have sexual intercourse for other reasons (table 11). The floor 
and ceiling effects were low. At the baseline, the analysed sample of 41 patients had the 
lowest score (i.e. best quality of life) on the dimension self image and sexual intercourse and 
highest score (i.e. worst quality of life) on the dimensions control and powerlessness and 
emotional well-being (table 11).  
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Table 11: Baseline data EHP-30 and data completeness after six and twelve months 
 
 
EHP-30  
 
Baseline (n=41) 
 
Complete questionnaires 
 
Mean (SD) 
Min-max 
 
Floor 
 
Ceiling 
 
rate 
 
% 
 
Pain  
Question 1-11 
 
51.3 (19.7) 
13.6-95.5 
n=40 
 
0/41 
 
0/41 
 
100/103 
 
97 
 
Control and powerlessness 
Question 12-17 
 
62.9 (21.3) 
8.3-100 
n=41 
 
0/41 
 
1/41 
 
100/103 
 
97 
 
Emotional well-being 
Question18-23 
 
53.9 (16.7) 
8.3-91.7 
n=38 
 
1/41 
 
0/41 
 
98/103 
 
95 
 
Social support 
Question24-27 
 
50.3 (21.6) 
0-93.7 
n=40 
 
1/41 
 
0/41 
 
102/103 
 
99 
 
Self-image 
Question28-30 
 
30.2 (18.3) 
0-58.3 
n=40 
 
2/41 
 
0/41 
 
102/103 
 
99 
 
Sexual intercourse 
QuestionC1-C5 
 
41.5 (25.6) 
0-100 
n=38 
 
3/41 
 
1/41 
 
92/103 
 
89 
 
 
 
 
On the pain-questionnaires, the participating patients were asked to estimate any changes in 
their overall pain level and after six months, 34 patients estimated their pain according to this 
question.  One patient was excluded from analysis since she could not be classified as pain 
free, better, same or worse. The improved group consisted of the patients that were classified 
as better or pain free (n=19) and the non-improved or stable group of patients that were 
classified as same or worse (n=14). 
 
The mean change on EHP-30 scores correlates with the patients’ own estimation of change 
in pain intensity, indicating that the pain intensity has an effect on all dimensions of quality 
of life (table 12). The improvement or deterioration in the quality of life was related to the 
improvement or deterioration in the pain intensity. 
The minimal important difference on the different EHP-30 scores in our material 
corresponds to the mean change for patients evaluating their pain to be better (n=17) and 
excluding the two that were pain-free (table 12).  
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Table 12, Change in EHP-30 in relation to change in pain intensity after six months 
 
EHP-30 
Worse 
n=8  
 
 
Meana (SD) 
Same 
n=6  
 
 
Meana (SD) 
Better= Minimal 
important difference 
n=17 
 
Meana (SD) 
Pain free  
n=2 
 
 
Meana (SD) 
 
Pain  
 
 
 
3.7(10.4) 
n=8 
 
-10.5 (10.4) 
n=5 
 
-19.9 (18.8)  
n=17 
 
-39.8 (37.0) 
n=2 
 
Control and 
powerlessness 
 
 
4.2(13.0) 
n=8 
 
-10.4 (16.6) 
n=6 
 
-25.7 (25.9)  
n=17 
 
-50.0 (23.6) 
n=2 
 
Emotional well-being 
 
9.5(14.6) 
n=7 
 
4.2 (20.7) 
n=6 
 
-13.9 (21.4)  
n=15 
 
-50.0 (17.7) 
n=2 
 
Social support 
 
 
 
0 (14.4) 
n=7 
 
-8.3 (17.5) 
n=6 
 
-12.9 (18.0)  
n=17 
 
-50.0 (26.5) 
n=2 
 
Self image 
 
 
 
4.8 (15.1) 
n=7 
 
-1.4 (12.3) 
n=6 
 
-6.9 (15.6)  
n=17 
 
-25 (23.6) 
n=2 
 
Sexual intercourse 
 
 
13.0 (16.0) 
n=5 
 
 
-3.0 (15.6) 
n=5 
 
-4.5 (27.8) 
n= 14 
 
-27.5 (3.5) 
n=2 
a  Negative values indicate improved Quality of Life 
  
 
 
Table 13: Effect size and significance of change in relation to change in pain intensity  
 
 
EHP-30 
Worse and same 
 n=14 
Better and pain-free  
n=19 
Effect sizea p-value 
paired t-test 
p-value 
Wilcoxon 
Effect sizea p-value 
paired t-test 
p-value 
Wilcoxon 
 
Pain  
 
-0.09 
 
0.62 
 
0.53 
 
-1.22 
 
0.0002 
 
0.0008 
 
Control and 
powerlessness 
 
-0.10 
 
0.63 
 
0.62 
 
-1.24 
 
0.0002 
 
0.001 
 
Emotional well-
being 
 
0.35 
 
0.16 
 
0.20 
 
-1.04 
 
0.006 
 
0.008 
 
Social support 
 
 
-0.17 
 
0.40 
 
0,42 
 
-0.84 
 
0.003 
 
0.006 
 
Self image 
 
 
0.11 
 
0.62 
 
0.44 
 
-0.51 
 
0.04 
 
0.03 
 
Sexual intercourse 
 
0.15 
 
0.38 
 
0.25 
 
-0.30 
 
0.29 
 
0.30 
 
a  Negative values on effect size indicate improved Quality of Life 
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For the patients in the improved group (better and pain free), the change in EHP-30 scores 
was significant for all dimensions but sex. The effect sizes for changes were large for all 
dimensions except “self image” (moderate change) and “sex” (small change, table 13). 
Significance of changes and effect sizes were also calculated for patients in the stable group 
(same and worse). There were no significant changes in any dimension on the EHP-30 
questionnaire in the stable group and the effect sizes were small indicating that there was 
little change in health status (table 13).  
 
The change in the different EHP-30 scores between the improved (better and pain free) and 
the stable group (same or worse) after six months were compared with independent student t-
test and Mann Whitney U test. There were significant differences for the change in EHP-30 
scores for pain, control and powerlessness and emotional well-being whereas there was a 
tendency for significance for social support and self image (table 14). The difference was not 
significant for the dimension sexual intercourse. 
 
Table 14, Change in EHP-30 for improved and not improved (stable) group 
 
 
EHP-30 
Patients´ estimated change in pain intensity 
Worse and same  
n=14  
 
Mean (SD) 
Better or pain-free  
n=19  
 
Mean (SD) 
p-value 
independent 
 t-test 
p-value 
Mann Whitney 
U test 
 
Pain  
 
-1.7 (12.3) 
n=13 
 
-22.0 (20.7) 
n=19 
 
0.004 
 
0.040 
 
Control and 
powerlessness 
 
-2.1 (15.9) 
n=14 
 
-28.3 (26.2) 
n=19 
 
0.002 
 
0.006 
 
Emotional well-being 
 
7.1 (17.1) 
n=13 
 
-18.1 (23.8) 
n=17 
 
0.003 
 
0.005 
 
Social support 
 
-3.8 (15.8) 
n=13 
 
-16.8 (21.6) 
n=19 
 
0.07 
 
0.08 
 
Self image 
 
 
1.9 (13.7) 
n=13 
 
-8.8 (16.8) 
n=19 
 
0.07 
 
0.13 
 
Sexual intercourse 
 
5 (17.2) 
n=10 
 
-7.3 (27.0) 
n=16 
 
0.21 
 
0.29 
 
 
The stable group was separated into two small subgroups and the effect sizes were calculated 
in the group that was “same” i.e. unchanged (n=6) and worse, (n=8) respectively.  
There were no significant changes in any EHP-30 score in the same group (p=0.08-0.64) or 
in the worse group (p=0.13-1). The effect sizes were small in both subgroups except on two 
scales in the subgroup that felt the same, in which the effect size were moderate for pain (-
0.79) and for control and powerlessness (-0.70). Thus, some of the scales displayed 
responsiveness in the small group that felt the same but for the other dimensions the effect 
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Table 15: Relative gene expression 
Relative gene expression (ΔΔCT-value) of MCP-1, IL-6 and IL-8 in macrophages and ECC cells after 
incubation with lignocaine 0.1 mg/ml for 24 h and 48h. The relative gene expression for each cell type and 
cytokine was compared with its own control (untreated cells, relative expression =1)) with Wilcoxon signed 
rank test. MØ: macrophages, ECC cells: endometriotic cyst capsule cells 
RNA  
Relative 
gene 
expression 
 
MØ endo. 24h 
N=5 
MØ healthy 24h 
N=5 
ECC cells 24h 
N=7 
ECC cells 48h 
N=7 
Rel. expr. 
Median 
Min-max 
p-value Rel. expr. 
Median 
Min-max 
p-value Rel. expr. 
Median 
Min-max 
p-value Rel. expr. 
Median 
Min-max 
p-
value 
MCP-1 0.91 
0.64-1.93 
0.69 0.71 
0.53-0.78 
0.043 1.21 
0.80-1.53 
0.13 1.02 
0.69-1.44 
0.87 
IL-6 0.65 
0.16-1.09 
0.08 0.72 
0.35-0.87 
0.043 0.94 
0.77-1.36 
0.87 1.00 
0.73-1.17 
0.74 
IL-8 0.86 
0.62-1.84 
0.50 0.50 
0.36-0.88 
0.043 0.87 
0.55-1.02 
0.03 0.94 
0.78-1.16 
0.31 
 
Table 16; Protein levels 
Protein levels correlated to RNA concentration (pg / µg RNA). Cells treated with Lignocaine 0.1 mg/ml for 24-
48h were compared to controls ( i.e. untreated cells of the same cell type at the same time point) with Wilcoxon 
rank sum test for matched pairs . MØ: macrophages, ECC cells: endometriotic cyst capsule cells 
 
Protein 
levels 
(pg/µg 
RNA) 
Cell types and treatment 
MØ endo. n=5 
24h 
MØ healthy n=4 
24h  
ECC cells n=7 
         24h                                48h 
Untreated 
 
Lignocaine Untreated Lignocaine  Untreated Lignocaine Untreated Lignocaine 
MCP-1 
Median 
Range 
9.31 
1.99-23.11 
n=3 
4.36 
1.97-29.1  
n=3 
5.13 
2.31-9.47 
 
3.84 
2.49-6.48 
2.80 
0.76-3.86 
1.83 
0.54-3.37 
2.21 
0.91-3.76 
2.39 
0.83-3.38 
p-value  p=1 p=0.47 p=0.13 p=0.74 
IL-6 
Median 
Range 
 
2.11 
1.02-4.51 
 
1.25 
0.79-4.60 
 
2.08 
1.54-5.05 
 
2.68 
1.19-4.02 
 
0.23 
0.10-0.78 
 
0.22 
0.15-0.52 
 
0.44 
0.12-0.98 
 
0.49 
0.14-1.78 
p-value  p=0.080 p=0.72 p=0.18 p=0.13 
IL-8 
Median 
range 
 
196.2 
71.5-498.1 
 
146.3 
99.9-673.0 
 
22.9 
18.2-69.7 
 
29.7 
14.7-85.8 
 
5.95 
4.46-15.06 
 
4.20 
2.55-9.36 
 
4.75 
2.96-8.15 
 
3.95 
3.16-7.14 
p-value  p=0.69 p=0.27 p=0.02 p=0.40 
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5.5.2.4 Differences between macrophages from healthy women and women with 
endometriosis  
Macrophages from patients with endometriosis produced significantly higher levels of IL-8 
in cell culture media compared to macrophages from healthy women. This was seen both 
without and with the supplement of lignocaine (MWU-test, p=0.02, table 16). No difference 
were seen between macrophages from healthy women and macrophages from women with 
endometriosis in the protein levels of IL-6 or MCP-1 (p=0.73-0.86, table 16). 
The relative gene expression and the relative protein secretion of the different cytokines 
(treated/untreated cells) were also compared between macrophages from healthy and 
endometriosis women. This corresponds to the cells reaction on lignocaine treatment. A 
tendency for different effect on gene expression was seen for IL-8 since macrophages from 
healthy women had lower relative gene expression compared to macrophages from patients 
with endometriosis (p=0.056, MWU test, table 15 and figure 10). There were no significant 
differences in relative gene expression between healthy and endometriosis macrophages for 
MCP-1 or IL-6 (p=0.22 and 0.55, figure 8 and 9). The relative protein secretion did not differ 
between macrophages from healthy or endometriosis women for any cytokine (p=0.56-0.90, 
figure 8-10). 
 
5.5.2.5 Differences between macrophages and stromal cells 
The macrophages from patients with endometriosis produced significantly more IL-6 and IL-
8 in cell culture media compared to ECC cells both with and without the supplement of 
lignocaine (p=0.003, MWU-test, table 16). The protein levels of MCP-1 in culture media did 
not differ between macrophages and ECC cells (p=0.12-0.18).   
When comparing relative gene expression and relative protein secretion (treated/untreated) 
between macrophages and ECC cells (MWU test) no differences were seen (gene expression 
p=0.10-0.88 and protein secretion p=0.22-0.83).  
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5.5.3 Cell staining on ECC cells  
The presence of vimentin was seen in the five ECC cultures, while cytokeratin was not observed, 
indicating that the cells were of stromal origin (figure 11).  
Figure 11; Immunofluorescence staining of ECC cells  Immunofluorescence staining of ECC cells 
showing red perinuclear staining for vimentin indicating stromal origin. 
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6 DISCUSSION 
 
6.1 GENERAL DISCUSSION 
Endometriosis is a chronic disease treated surgically with resection of endometriotic tissue or 
pharmacologically (108). Hormonal therapeutic approaches currently used for amelioration 
of endometriosis-associated pelvic pain all inhibit ovulation, have side effects and do not 
improve subsequent spontaneous fertility (106).  
There is a need for new treatment options for patients with endometriosis. An optimal new 
treatment should be efficacious on both pain symptoms and fertility. It should have few and 
acceptable side effects, not be contraceptive, not interfere with ovulation or the implantation 
capacity of the endometrium and not have teratogenic effects. A new treatment would 
preferably inhibit the growth and the development of endometriotic lesions and improve the 
chances of natural conception.  
Pertubation with lignocaine represents an alternative non-hormonal treatment strategy. The 
first clinical trial of pertubations with lignocaine was carried out after an in vitro study on 
peritoneal macrophages (128). Patients with endometriosis, infertility and patent Fallopian 
tubes were offered pre-ovulatory pertubations in a double-blind cross-over study and 32 % 
of patients who did not become pregnant reported reduced dysmenorrhea (135). A separate 
study intended to investigate the effect on pain showed promising results since five of six 
patients treated with lignocaine 1mg/ml reported reduced dysmenorrhea (137). Lignocaine 
affects inflammatory cells but might also affect other cells involved in the pathophysiology 
of endometriosis such as glandular and stromal cells in eutopic and ectopic endometrium 
and sensory nerves.  
The objective of the studies presented in this thesis was to further evaluate the effect of 
lignocaine pertubations on pain and quality of life, to evaluate the safety behind the method 
and to examine some effects of lignocaine in vitro.  
The results indicate that pertubation with a low dosage of lignocaine can improve 
dysmenorrhea and quality of life in some patients with endometriosis. The procedure seems 
to be safe and without side effects related to lignocaine. The cell culture study suggests that 
lignocaine may affect the gene expression and secretion of some pro-inflammatory cytokines 
involved in endometriosis and this could be an explanation for the subtle clinical effect seen 
on dysmenorrhea and quality of life.  
The optimal dosage and therapy intervals are not known but the pharmacokinetic study 
indicates that it would be safe to pertubate higher dosages of lignocaine.  
In the following discussion both advantages and disadvantages in the included studies are 
addressed. Also a discussion around the results, implications and possible future studies will 
follow. 
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6.2 DISCUSSION PAPER I 
The PP analysis demonstrated a significant pain reduction on the VAS scale after three 
pertubations with lignocaine compared to placebo but no significant effect was seen in the ITT 
population.  
In the preceding study by Edelstam et al., the effect on dysmenorrhea was evaluated only with 
the patients’ own estimation of change in pain intensity (137). In the presented RCT, the VAS 
scale was chosen for primary evaluation and the definition of success was set rather high since 
we wanted to exclude the placebo effect. This might be an explanation for the different rates of 
success between the small study on which the power calculation was based and the present thesis 
(83% and 42% respectively).  
There are few studies defining criteria for relevant improvement on the VAS-scale. A 
randomised study evaluating the effect of laparoscopic uterine nerve ablation in women with 
chronic pelvic pain defined improvement as >50% on the VAS-scale from baseline (100). The 
expected placebo effect could probably be excluded if improvement was defined as >50% on the 
VAS scale, and this level was therefore used. In a study based on two small RCTs, the best 
separation between women rating themselves “minimally improved” and “improved” was found 
to be a decrease of 28 mm on the VAS-scale (163). Such a low definition of success did not 
allow a distinction of treatment effect from placebo effect in our study. The average strength of 
placebos upon pain on a visual analogue scale is 2 out of 10 units (176, 177). Individuals who 
respond to placebos may show even greater effects up to 5 out of 10 units (174). 
When analysing the present results with other definitions of success, e.g. ≥ 40 mm decrease on 
the VAS scale or obtaining a VAS below 20mm, similar results were obtained as with 
improvement ≥ 50% on the VAS scale. Also these levels were assumed to exclude the placebo 
effect or the effect of reporting bias. Unpublished data indicate that the MID on the VAS scale in 
the present study population is a decrease around 37 mm or 50%. When using a decrease >37mm 
on the VAS scale as cut of, there are 9/24 in lignocaine and 2/18 in placebo group obtaining 
success in the ITT analysis (p= 0.080) and in the PP population the results are 9/20 and 1/14 
respectively (p=0.024).  
If the definition for success is set even higher, for example total pain relief, no patient in the 
placebo group obtained success. Four patients in the lignocaine group (17%) were pain free 
during periods after three pertubations compared to none in the placebo group (Fisher exact test, 
p=0.12) and the evaluated pain level on the VAS scale was only 0-4 (of 100).   
It is interesting to note the long-term effect in ten patients in the PP population who improved 
≥50% on the VAS scale. Nine of these were in the lignocaine group and the reduced pain level 
lasted up to one year after the first treatment. There is no apparent explanation of this long-term 
effect; however, macrophages have a long lifespan, ranging from months to years (183) and the 
effect might depend on permanent cellular effects (73, 116). Macrophages can switch their 
activation status from a pro-inflammatory to an anti-inflammatory state and the same 
macrophages can thereby participate in both the induction and the resolution of inflammation 
(184).  In chronic inflammatory diseases, the inhibition of the apoptotic program promotes 
monocyte survival contributing to the accumulation of macrophages and the persistence of an 
inflammatory milieu (185).  
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The results of the pertubations with lignocaine or placebo were analysed in the PP and the ITT 
populations respectively since earlier studies had given indications that the effect on pain 
improved after repeated treatments (135). The reasons for not receiving the three treatments 
during three consecutive months were similar between groups and included bacterial vaginosis 
as well as patients on occasional vacation. Unfortunately, four patients did not fulfil the inclusion 
criteria VAS < 50 mm at inclusion and were therefore excluded from PP analysis. The chance of 
improvement >40 mm on the VAS scale is more or less eradicated if you start at a VAS below 
50 mm.  
No significant differences were seen in the success rate on the VAS scale between the lignocaine 
and the placebo groups three to nine months after the last treatment. This can be due to the small 
sample size, getting smaller for every time point.   
Additional calculations presented in this thesis using the VAS scale as a continuous variable 
showed a significantly larger decrease on the VAS scale (with MWU test) in the lignocaine 
group after nine months compared to the placebo group. Even though a significant difference 
was seen, the clinical importance of this finding can be argued. The mean change in the 
lignocaine group was below the suggested MID and may therefore not be perceived by the 
patients and also the spread in the VAS change was large in both groups. These additional 
statistical analyses were exploratory and dichotomising the results in success/failure, using a cut 
off like the MID, is considered a better way to interpret the results in studies involving PRO. 
Also, the power analysis was based on proportions and there were no preliminary results 
considering changes on the VAS scale after lignocaine pertubations.  
There were no significant differences between the groups when analysing the sum of scores from 
the categorical scales.  The patients’ change in function because of pain was equal with small 
improvements in both groups. Many patients had difficulty in graduating their function level on 
the categorical scales and continuous scales may be more sensitive to small changes compared to 
categorical scales. 
Since no significant differences between treatment and placebo groups were seen in the ITT 
population, one could argue that an effect of lignocaine pertubations on pain could not be 
demonstrated. However, if using the MID on the VAS scale from the present sample there was a 
trend for larger improvement in the lignocaine group (p=0.10 for 50% and p=0.08 for 37mm) 
even in the ITT group. The significant effect on pain found in the PP population might be a 
coincidence but correspond to the effect on dysmenorrhea seen in the previous studies.  
 
6.3 DISCUSSION PAPER III 
Women with endometriosis have impaired HRQL compared to women without endometriosis 
and the QOL is related to the degree of pain. We hypothesized that pertubation with lignocaine 
could improve QOL in patients with endometriosis. A significantly larger improvement was 
found in the lignocaine group on the social support scale of the EHP-30 at six months. The four 
questions in the dimension social support measure the impact of endometriosis upon a woman´s 
social support network and reflect the patients feeling about her relations and her self confidence 
in social relations (Appendix 9.2)(167).  
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The baseline EHP-30 scores and demographics were comparable between the lignocaine and 
the placebo groups and the present baseline data on the EHP-30 is consistent with studies 
from other countries (153, 161, 165, 186-189). As in other populations, the highest score (i.e. 
worst quality of life) was found on the dimension control and powerlessness. 
The lack of differences between the groups in 5/6 of the dimensions after six months was 
expected since the decrease in pain on the VAS scale was not significantly different between the 
groups after six months. After twelve months the sample size was probably too small to detect 
small differences between groups. Pertubation with lignocaine affects the degree of pain 
immediately after three pertubations i.e. approximately four months after the first treatment.  The 
EHP-30 was not collected at this time-point since previous studies had shown long term effect. 
The EHP-30 questionnaire is extensive and in order to obtain good compliance, it was only 
collected at six and 12 months. One can speculate whether the effect on QOL had been more 
pronounced if the EHP-30 also had been collected after four month. 
Although there was no difference in change in the pain intensity on the VAS scale after six 
months, a significant difference between the treatment and the placebo groups was seen for the 
dimension social support on the EHP-30. It has earlier been shown that HRQL depends on the 
degree of pain but other questionnaires were then used (19, 26). In the Short form-36 (SF-36) the 
social functioning score measures the impact of illness on the patient´s ability to continue with 
social activities whereas the social support dimension on the EHP-30 questionnaire measure the 
impact of endometriosis upon a woman´s social support network. The social support dimension 
on the EHP-30 questionnaire is probably related to the pain intensity even if the change in pain 
was similar between the groups after six months. Since the patients in the lignocaine group had 
significantly lower pain intensity two months before the second EHP-30 was filled out, it would 
be expected that the effect on social support was revealed thereafter and still depend on the pain 
intensity. Since the social support scale on the EHP-30 rather reflects the patients feeling about 
her relations, it would be expected that when she gets pain relief from the treatment, it might take 
some months to improve her self-confidence in social relations. Moreover, the effect seen on 
social support after six months might be a sustained effect from the hypothetic improved QOL 
two months earlier (when there was an effect on pain intensity). 
Those who improved >50% on the VAS scale after four months had significantly better score on 
social support after six months (p=0.005) compared to those who did not improve. Other 
observations on the material show that many dimensions on the EHP-30 are related to the pain 
intensity and are affected when the pain level decreases more than 50% or if the maximum pain 
level reaches <20 mm on the VAS scale (unpublished data). Pertubation with lignocaine could 
have effects on quality of life independent on pain intensity even if the effect most probably is 
related to a lower pain level.  
The power analysis was based on the change on the VAS-scale after 4 months and the EHP-30 
questionnaire was a secondary outcome. Therefore the third study is probably underpowered and 
a larger sample size could be needed to fully answer the hypothesis of this study. Twelve 
parameters were evaluated (six dimensions at two time points) and the effect on social support 
might be a random finding i.e. due to mass significance.  
It is difficult to interpret the results of PRO measures and the use of MID has been proposed 
to be helpful on this issue. The proportion of patients improving above the MID were 
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somewhat larger in the lignocaine group compared to the placebo group in 10 of 12 
measurements but there were no significant differences except for social support after six 
months (Fisher´s exact test, p=0.036). An improvement above the MID is considered 
clinically significant and it is important to notice that the significant effect seen on social 
support could also be perceived by the patients.  
 
6.4 DISCUSSION PAPER I AND III 
Even in the placebo group there were patients that improved somewhat regarding pain and 
HRQL. This might be a placebo effect when participating in a clinical study.  After four 
months, the mean effect of pertubation with placebo was 22.5 mm on the VAS scale, which 
is an effect of placebo in accordance with earlier studies (176, 177). Considerable effects on 
QOL were found in the placebo group after six months on the pain and the control and 
powerlessness scores. Placebo can have benefits in studies with continuous subjective and 
patient reported outcomes, for the treatment of pain and when a physical placebo 
intervention is used (179). A measurable placebo effect was therefore expected in the studies 
but is difficult to distinguish from biased reporting. The effect of placebo might improve any 
well-being in this population and be a confounder in a relatively small study.  
In another RCT on patients with endometriosis, the placebo group demonstrated a significant 
improvement in the quality of life as measured by the SF-36 (26). 
Some difficulties to include women in the study were expected since the preceding study 
by Edelstam et al. had to be terminated earlier due to difficulties of recruiting enough 
patients. Also in this study, the recruitment of patients was more difficult than expected. In 
total, 106 women were interested in participating, but 53 of them were not scheduled for a 
screening visit since they did not fulfil the inclusion criteria or were not interested after 
information had been given. Women with endometriosis and pain are hesitant to participate 
in a randomised study including placebo and therefore the present study was designed with 
unequal randomisation (4 treatment: 3 placebo) in order for more subjects to have a chance 
for treatment. Although previous studies indicated that lignocaine might be more effective, 
the study was designed to evaluate if treatment with lignocaine or placebo were the most 
effective. Every gynaecological examination is a potentially painful procedure for 
endometriosis patients and this, in combination with practical reasons such as geographic 
distance, were of importance for choosing not to participate. Many women did not fulfil 
inclusion criteria and the most common reason was a present wish for pregnancy. No 
further investigation on baseline characteristics for patients choosing not to participate has 
been conducted. 
Women who have severe dysmenorrhea and side effects on medical treatments are more inclined 
to participate in a non-hormonal clinical trial. The fact that patients that have failed to improve 
on other treatments are attracted to clinical trials might constitute an attenuation biased group. 
The study also attracted women who had a wish for pregnancy since earlier studies had shown an 
effect on fertility. Even though they claimed no wish for pregnancy at inclusion, as many as six 
patients went through IVF after the three treatments had been given and were therefore lost to 
follow up. Also two women in lignocaine group who conceived naturally during the study were 
lost to follow up due to normal pregnancies. All children born after lignocaine pertubations were 
healthy. 
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Eleven women were withdrawn from the study because of pregnancy or need for other 
therapies and the drop-out rate was equal between the groups. Also the number of missing 
questionnaires was equal between groups. No analysis has been made on the patients that did 
not send in all questionnaires. A possible reason for not sending in the questionnaires could 
be disappointment due to lack of improvement after treatment. If that would be the reason, 
the results might be exaggerated since adding these missing questionnaires would dilute the 
effect in both lignocaine and placebo groups.  
Since the present study is a double blind RCT, the risk for bias is considered to be low. The 
objective of randomisation is obtaining similar groups, however the small number of patients 
can be of more concern. The first and third studies have limitations due to the small sample 
size but the design contributes to the strength. 
 
6.5 DISCUSSION PAPER II 
Pertubation with lignocaine is safe.  The serum levels of lignocaine following pertubation of 10 
mg lignocaine hydrochloride are detectable but low. The highest level was 0.124μg/ml, which is 
about 80 times below the toxic level of 10μg/ml. The concentrations detected are consistent with 
other studies and correspond to the low dose pertubated (139). Study II support the theory that 
lignocaine pertubated through the fallopian tubes reaches the peritoneal cavity and diffuses 
through peritoneum into the blood circulation. The levels rose during the follow up time and the 
highest values were observed after 30 minutes. The major part of the pertubated fluid is thought 
to reach the peritoneal cavity but some lignocaine might also be absorbed by the endometrium or 
by the lining of the fallopian tubes during the pertubation process of approximately 5 minutes.  
Lignocaine is a potent drug and a potential risk would be a high dosage of lignocaine in the 
central circulation. During the pertubation treatment the solution is infused into the uterine cavity 
and could possibly by accident be placed directly into a blood vessel. However, if the solution 
had accidently been infused in a vessel, the concentration in serum would have risen much faster. 
One patient had her highest level after 5 minutes but the level was very low (0.090 µg/ml).  
The study has limitations due to the short follow up time and pharmacokinetics with Cmax 
and Tmax could therefore not be calculated. The sampling was not performed for longer 
time than 30 minutes after pertubation due to considerations for the patients. Earlier 
pharmacokinetic studies after intraperitoneal administration had indicated a Tmax ranging 
from 5 to 40 minutes and six of seven studies with plain lignocaine had a Tmax ranging 
between 5 and 30 minutes (139). The absorption of lignocaine was expected to be faster 
and the slower absorption registered might be due to the fact that no abdominal operation 
was carried out, which was the case in all of the reviewed studies. The Tmax for lignocaine 
ranges between 15 and 30 minutes after injection for dental anaesthesia as well as after a 
subcutaneous injection (138, 140). According to earlier studies the Tmax in our study is 
probably around 30 minutes and is unlikely to be above 40 minutes. Accordingly the Cmax 
could impossibly reach above 0.20 µg/ml after pertubation of 10 mg lignocaine. 
The pertubation dosage of 10 mg was chosen as a safety precaution due to a minimal risk for 
depositing the substance directly into the circulation. An intravenous injection of 10 mg of 
lignocaine is known to be safe and the dosage would be far below the initial dosage for treatment 
of ventricular arrhythmia. An initial dose of 50-100 mg is then given intravenously (0.5-1.0 
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mg/kg bodyweight) as compared to the pertubated dose of 10 mg/70kg, approximately 0.14 
mg/kg bodyweight.  
Present data together with previous pharmacokinetic studies of lignocaine, confirm the 
hypothesis that pertubation with 10 mg lignocaine produce very low and therefore safe levels of 
lignocaine in serum.  
The risk for pelvic infections secondary to repeated intra-uterine instrumentation and 
instillation are negligible. Only non-patent / post inflammatory tubes constitute a risk for 
infection (190). There are no reports on any infectious complications after repeated 
pertubation procedures such as Fallopian Sperm Perfusion for unexplained infertility and 
patent Fallopian tubes. LAs also possess antimicrobiological properties in vitro and in vivo 
(116) and patients treated with lignocaine are not more susceptible to infections (119). 
 
6.6 DISCUSSION PAPER IV 
The EHP-30 questionnaire used was a Swedish translation used by Pharmacia UpJohn 2001, 
which was available at the research unit at Danderyd hospital. The items in Swedish were 
compared to the English original version and seemed to be correctly translated with no obvious 
linguistical or conceptual differences between the original and translated versions. In 2010, a 
new translation to Swedish was performed by Isis Innovation, the owner of the EHP-30 
questionnaire. When comparing the used translation with the translation by Isis Innovation, only 
minor linguistic changes between the translations were found (Appendix 9.2 and 9.3). 
Adaption of a questionnaire to other languages includes not only translation of items and 
response scales (152). The psychometric properties of the questionnaire may differ between 
different cultures and ideally a questionnaire should be evaluated and adapted in each 
population. It is important that the concepts assessed by each item should be as identical as 
possible, the aggregation of items should result in the same constructs and the metric of 
scales should be similar. 
The EHP-30 is recommended as an outcome measure in clinical trials involving patients with 
endometriosis and pain and has been shown to be more responsive to change than the general 
questionnaire SF-36 (153). Even if the EHP-30 has not yet been validated in Swedish, it was 
considered the best available option since it is the only QOL scale that has been validated for use 
in women with endometriosis (74). The cultures in Sweden and Great Britain are not very 
different and the psychometric properties of the EHP-30 questionnaire are most probably similar 
in the Swedish and the English version. The Dutch version of the EHP-30 has been showed to be 
reliable, valid and responsive to change (165, 187). Most translation guidelines assume that 
constructs are relevant and equivalent across cultures (152, 191). However, a validation of the 
Swedish version preceding the clinical trial would have been preferable. The core questionnaire 
and the sexual intercourse questions were available in Swedish at the research unit and were 
therefore used. Using the whole questionnaire might affect compliance and was not an option. 
The score concerning sexual intercourse were included since this is a frequent problem for 
women with endometriosis (25, 145). The general details and the general health questions in the 
EHP-30 questionnaire were not included but similar data were gathered in the CRF (Case record 
form).  
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The EHP-30 questionnaire translated to Swedish seems to be acceptable, understandable and 
applicable. Data completeness for the core scales were high for all dimensions (89-99%) and 
only a few questions remained unanswered. The sexual intercourse scale was the one with 
most missing items and not all women were sexually active at the different time points. 
About half of the women that did not have sex avoided intercourse because of pain and the 
other half lacked sexual partner at that specific time point. Due to pelvic pain and subsequent 
relation problems, absence or infrequent intercourse is common among women with 
endometriosis. The relatively low dropout rate was probably partly due to a limited number 
of modular items. The sample in this clinical trial seems to have normal distributions on all 
the different scores with few patients at extreme values.  
It is important that the QOL questionnaires used in clinical trials are responsive to change and it 
is recommended to confirm responsiveness across multiple samples (150). Also, to be able to 
trust the QOL result, it was important to demonstrate responsiveness of the EHP-30 in the study 
population. The social support scale on the EHP-30 questionnaire failed to demonstrate 
responsiveness in a sample of 40 women in the U.K. (153) but did show responsiveness in a 
larger sample of 228 women in the Netherlands (165). In our material, the EHP-30 questionnaire 
seems to be highly responsive to change for all scales on the core questionnaire. The study 
sample was small but equal to the sample size used by Jones et al. when initially evaluating the 
responsiveness of the questionnaire (153).  
In the improved group there were significant changes on all core scales on the EHP-30 
questionnaire and the effect sizes were moderate to large, indicating that the EHP-30 is 
highly responsive to change. Similar to earlier studies, the most responsive scales were pain 
and control and powerlessness (153, 165).  No significant changes in any dimension on the 
EHP-30 were seen in the stable group and the effect sizes were small indicating little change 
in health status. 
It is vital that a HRQL questionnaire to be used in a clinical trial can discriminate between 
improved and non-improved patients. Data presented in this thesis indicate that the EHP-30 
questionnaire is well suited for this purpose. Significant differences were found between the 
improved and the stable groups for the change in EHP-30 scores for pain, control and 
powerlessness and emotional well-being whereas a tendency for significance was seen for 
social support and self image.  
 
The HRQL is related to pain intensity in the present study. A correlation between the mean 
change on the EHP-30 scores and the patients own estimation of change in pain intensity was 
found. The fact that pain intensity is correlated with QOL is in concordance with earlier 
studies (19, 26). We used the patients´ estimation of change in pain intensity as an anchor to 
evaluate responsiveness since pain has relationship with HRQL (150).   
 
In the small group of patients that evaluated their pain to be the same (n=6) the effect sizes for 
pain and control and powerlessness were moderate but there were no significant changes (paired 
t-test) in the different EHP-30 scores. Thus, some of the scales displayed responsiveness in the 
small group that felt the same but for the other dimensions the effect sizes were small, indicating 
small changes in quality of life for patients reporting themselves to feel the same. Although some 
of the scales were responsive for the stable group, in all cases they were less responsive than in 
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the improved group. Similar results have been obtained when Colwell´s QOL questionnaire was 
evaluated, displaying responsiveness on some of the scales in the stable group (145). Even in the 
Dutch population, small improvements were seen in the non-change group (165). The reason for 
improved QOL, even if the pain intensity was estimated to be the same, might be a placebo 
effect when participating in a clinical study or an effect of reporting bias (178, 179, 192). 
The EHP-30 questionnaire does not seem to be as responsive for deterioration as it is for 
improvement. For patients that felt worse in pain intensity, the effect sizes were much smaller 
than in the improved group and the changes on the different EHP-30 scores were not significant. 
There is evidence for asymmetry in worsening and improvement in patient reported outcomes 
(150). The asymmetry in our data is in accordance with Colwell´s QOL questionnaire, where 
responsiveness was found to be moderate to high for the patients who improved but low to 
moderate in the impaired group (145). Also in a Dutch study evaluating the responsiveness of the 
EHP-30 questionnaire, the changes in scores for those who deteriorated were smaller than the 
changes in the improved group (165). 
Only the EHP-30 questionnaires collected after six months were used in the responsiveness 
analysis. This was due to a smaller sample size at twelve months and the fact that a longer 
time had passed since inclusion, making the patients own evaluation of change in pain 
intensity more unreliable.  
 
The MID may vary by population and context and no level for MID will be valid for all 
study applications involving a PRO instrument (150, 171). In the study population, the MID 
levels on the EHP-30 questionnaire were higher for emotional well-being and social support 
but lower for control and powerlessness, pain and self confidence compared to the levels in 
Jones´ study, based on 40 patients (153).  The MIDs in the present data were larger for all 
dimensions in comparison with the study by van de Burgt et al. (165). The MID in social 
support was -13 compared to -10 in the Dutch study and +1.7 in the British study  supporting 
the thesis that the EHP-30 questionnaire is sensitive to change even for the dimension social 
support.  
 
To be able to compare our results with the study by Jones et al. the same parametric tests were 
used (153). Mostly parametric tests are used when evaluating responsiveness (147). However, in 
this small study in which an ordinal scale was used it would have been more appropriate with 
non-parametric tests even though the data seemed to be normally distributed. The results in this 
thesis have been complemented with non-parametric tests and similar results were obtained. 
Data from the fourth study show that the EHP-30 is sensitive to change on all dimensions on the 
core questionnaire and can detect differences in health related quality of life at a level that is 
important and detectable for the patients.   
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6.7 DISCUSSION PAPER V 
It was hypothesized that lignocaine could attenuate the gene expression and the release of 
the pro inflammatory cytokines IL-6, IL-8 and MCP-1 in vitro. The main finding was a 
significant decrease in both the gene expression and the protein secretion of IL-8 in 
endometriotic stromal cells after incubation with lignocaine 0.1 mg/ml for 24h.  
Lignocaine has been shown to decrease cytokine release both in vitro and in vivo but it is 
not known whether this is due to a reduced gene expression and synthesis of the cytokine 
or decreased cellular secretion (122). The present data is in accordance with a study on 
epithelial cells, in which both the secretion and the transcription of IL-8 was reduced by 
treatment with lignocaine (118). A tendency for both lower gene expression and protein 
secretion of IL-6 was found in macrophages from endometriosis patients treated with 
lignocaine. In contrast, for the healthy macrophages the gene expressions were lower for 
all tested cytokines whereas no significant differences on protein levels were found. The 
mechanism for the effect of lignocaine is thereby still unknown and may differ between 
different cell types.  
Lignocaine 0.1mg/ml correspond to a concentration of 0.43 mM since the molecular weight 
of lignocaine is 234 Da. Lignocaine at higher concentrations than 0.5 mg/ml, had effect on 
both proliferation and viability and could therefore be considered to be cell toxic. This was 
also seen after RNA preparation where the RNA concentration was considerably lower after 
incubation with lignocaine 1.0 mg/ml. Therefore the incubations with lignocaine 1.0 mg/ml 
were excluded from further analysis.  
It can be presumed that lignocaine 0.1 mg/ml is not toxic to cells in vitro even though a 
significant decrease in viability was seen at 0.05 and 0.1 mg/ml compared to the control after 
24 h. The proliferation at the same concentration and time-point was not affected and the 
spread between samples was large. The effect of lignocaine on cell viability has been 
evaluated in other studies. A lignocaine dosage of 0.4 mg/ml for 24 h did not affect the 
viability of adipose stem cells in culture compared to controls whereas concentrations of 0.8 
mg/ml and 1.6 mg/ml showed a significantly increased cytotoxicity (193). Other studies have 
shown no effect on the viability of epithelial cell after exposure to lignocaine 0.23 mg/ml for 
24h (118) or of endothelial cells after exposure to lignocaine 0.5 mg/ml for 4h (131).  
 
The dosage of 0.1 mg/ml used corresponds to the probable situation in vivo after pertubation 
with 10 mg lignocaine. The peritoneal fluid dilutes the dosage of 10 mg in the clinical studies 
and corresponds to an approximated intraperitoneal lignocaine-concentration of 0.1-0.3 
mg/ml. Other in vitro studies evaluating the effect of lignocaine on cytokine levels used 
concentrations ranging from 0.011-0.7 mg/ml and the cells were incubated with lignocaine 
for 4h-24h (118, 129, 131). A maximal effect on cytokine secretion was seen at a lignocaine 
concentration of 0.23 mg/ml when epithelial cells were cultured for 24h (118). 
 
IL-8 is thought to play a role in the pathogenesis and maintenance of endometriosis since it  
may act as an autocrine growth factor in the endometrium (29). Lower concentrations of IL-8 
in the PF could have beneficial effects on both the symptoms and the progression of 
endometriosis. The lower gene expression and secretion of IL-8 in endometriotic stromal 
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cells in our study can thus be part of an explanation for the clinical effect seen on pain and 
fertility after pertubation of lignocaine in vivo.  
 
The macrophages from women with endometriosis had a significantly higher production of 
IL-8 compared to macrophages from healthy women, which is in concordance with earlier 
studies. Macrophages from patients with endometriosis are more activated compared to 
macrophages from healthy women (28). The increased concentration of IL-8 in the PF of 
patients with endometriosis has been suggested to be derived from peritoneal macrophages 
(51, 194).  The IL-6 response in peritoneal macrophages and endometrial stromal cells 
have been found to be dysregulated in patients with endometriosis (195).  
Macrophages from patients with endometriosis and healthy controls reacted different on 
treatment with lignocaine.  All cell cultures from healthy women (n=5) showed a decreased 
gene expression of all the tested pro-inflammatory cytokines after incubation with lignocaine 
compared to untreated cells from the same healthy women. In contrast, lignocaine had 
diverging effects on gene expression in the macrophages from patients with endometriosis 
since three of five samples showed increased gene expression of one (n=2) or two (n=1) 
cytokines after lignocaine treatment. 
These results indicate that some patients with endometriosis may have macrophages that are 
altered and do not react normally. This could be an explanation for the fact that the clinical 
effect on pain after pertubation with lignocaine differed between patients.  
 
After 48 h incubation with lignocaine, no differences were seen in gene expression or protein 
levels of MCP-1, IL-6 and IL-8 in endometriotic stromal cells. This was somewhat 
surprising since a pilot study on only one sample showed lower concentrations of MCP-1 
after both 24 h and 48 h and we had expected the same trend in this larger study of 7 patients. 
As with the macrophages, also the endometriotic stromal cells might differ between patients 
with endometriosis and subsequently some patients might benefit from lignocaine 
pertubations whereas others might not. The diverging reactions in stromal cells after 
treatment with lignocaine illustrate the importance of larger studies with several samples. 
The sample size of seven can be seen as strength in this in vitro study but even more patients 
would have been preferable.  
 
There were economic reasons for choosing only three cytokines in the in vitro study. IL-6, 
IL-8 and MCP-1 was chosen since their levels in peritoneal fluid are related to the severity of 
endometriosis, since they are all believed to be involved in the pathogenesis of endometriosis 
and since they are all secreted by both macrophages and ectopic endometrial cells (stromal 
and epithelial cells).  
 
6.8 IMPLICATIONS 
Pertubation with lignocaine can be developed to be a new non-hormonal treatment option for 
endometriosis-related menstrual pain in patients with minimal to moderate endometriosis.  
The data presented in this thesis is not strong enough to prove the effect of lignocaine 
pertubations on endometriosis associated pain but can act as a platform for future studies. 
The study population represents a small and selected part of the whole endometriosis 
population and might not be representative for all patients with endometriosis. However, it 
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represent patients that have a need for non-hormonal therapies due to side effects, patients 
with a wish for pregnancy and patients who have failed to improve on other treatments. 
Since these patients are common in clinical endometriosis practice, at least some of the 
results can probably be transformed on the whole endometriosis population. 
 
 
6.9 FUTURE PERSPECTIVES 
Well-designed clinical and cellular studies are needed to support the potent anti-
inflammatory effects of LAs in various clinical conditions and to form a platform for future 
treatments of inflammation (115, 116). 
The optimal dosage and therapy intervals for the clinical effect seen on fertility and pain are not 
known. Studies are in progress to further evaluate the effect on pain and to assess the optimal 
dosage and therapy intervals. The pharmacokinetic study gives indications that it would be 
possible to try a higher dosage with preserved safety. With a higher dosage it could be possible 
to give fewer treatments or to have longer therapy intervals. 
In a forthcoming phase III study, the effect on pain, quality of life and fertility could be 
evaluated in a larger sample. The number of exclusion criteria could be reduced to make the 
inclusion of patients easier. For example, patients with a present wish for pregnancy and 
women on continuous OC due to pelvic pain could be included. This would also reduce the 
risk of bias. After the last pertubation, the HRQL should be evaluated during the subsequent 
period and maybe more frequently thereafter. There is a need for an additional 
pharmacokinetic study with longer follow up and maybe different dosages.  
It is obvious that some patients benefit from lignocaine pertubations whereas others have no 
effect at all. This could also be seen at a cellular level. A larger study could help us identify 
those with highest chance for improvement. Identifiable factors that might have an effect on 
outcome are duration of endometriosis, fertility, age, smoking, concomitant depression, 
baseline quality of life, baseline pain level during and between periods and effects of 
previous treatments. 
 
In more advanced endometriosis, one could evaluate the effect of lignocaine on pain if 
deposed in the peritoneal cavity during diagnostic or therapeutic laparoscopy. 
 
Pertubation with lignocaine probably affects the endometrium during its passage and have 
effect on fertility which would be interesting to investigate at a pathohistological level. 
Maybe the sensory nerve fibres or levels of cytokines in the endometrium are affected by 
lignocaine, leading to a higher implantation rate.  
The mechanism of lignocaine on peritoneal macrophages and ectopic endometrium in vitro 
needs to be further investigated. In cellular studies it would be interesting to investigate other 
dosages of lignocaine, other treatment durations, other cytokines and also other types of cells 
i.e. ectopic epithelial cells. A somewhat higher concentration of lignocaine may give other 
results since one study has shown maximal effect on cytokine secretion at a lignocaine 
concentration of 0.23 mg/ml (118). 
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7 CONCLUSIONS 
 
Pertubation with lignocaine can relieve pain in some patients with endometriosis and might 
be developed to be a new non-hormonal treatment option for endometriosis-related pain in 
patients with minimal to moderate endometriosis. During pertubation treatments, ovulatory 
cycles can be maintained and fertility preserved. The treatment is easy to perform with good 
safety in an outpatient setting.  
 
Lignocaine pertubated through the fallopian tubes reaches the peritoneal cavity and diffuses 
through the peritoneum into the blood circulation. The serum levels of lignocaine following 
pertubation of 10 mg lignocaine hydrochloride are detectable but low. Pertubation with 
lignocaine is safe, well tolerated and have no adverse events related to lignocaine. 
 
Pertubations with lignocaine might improve the social support dimension of quality of life in 
patients with endometriosis. The effect is probably due to decreased pain levels during the 
preceding months. To further evaluate the effect of lignocaine pertubations on quality of life, a 
larger study with more frequent follow up time points is required. 
 
The EHP-30 is responsive to improvement on all dimensions on the core questionnaire. The 
Swedish version of the EHP-30 questionnaires used in the present thesis seems to be 
acceptable, understandable and applicable in our Swedish material. Quality of life is related 
to the degree of pain.  
 
Lignocaine inhibit the gene expression and secretion of IL-8 in endometriotic stromal cells. 
Further, lignocaine inhibit the gene expression of IL-6, IL-8 and MCP-1 in healthy 
macrophages in vitro. Macrophages from women with endometriosis might be dysregulated.  
The data presented in this thesis indicate that due to differences at cellular level, nearly half 
of the endometriosis population may benefit from lignocaine pertubations. 
 
Thus, the findings of this thesis support the hypothesis that pertubation with lignocaine can 
relieve pain in some patients with endometriosis and that the treatment could also have an effect 
on Quality of Life. The in vitro study demonstrate that lignocaine have cellular effects in low 
concentrations which is promising for the development of lignocaine-pertubations as a new non-
hormonal treatment for pain due to endometriosis.  
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8 POPULÄRVETENSKAPLIG SAMMANFATTNING 
 
Bakgrund endometrios 
Endometrios är en relativt vanlig sjukdom som drabbar 6-10 % av kvinnor i fertil ålder och upp till 50 
% av kvinnor med mensvärk och infertilitet (5-8). Vid endometrios förekommer livmoderslemhinna 
på andra ställen än i livmodern, oftast på bukhinnan i nedre delen av buken och på äggstockarna . 
Sammanväxningar kring äggstockar och äggledare kan uppstå vilket kan skada anatomin och 
försämra passagen i äggledarna (3).  
De vanligaste symtomen vid endometrios är mensvärk, smärta i nedre delen av buken mellan 
menstruationerna och nedsatt fertilitet (5-8). Kvinnor med endometrios har oftare än andra kvinnor 
depression och ångest vilket är relaterat till graden av smärta (19-21). Även så kallad hälsorelaterad 
livskvalitet är försämrad hos kvinnor med endometrios (19, 23) beroende på långvarig smärta (19, 24, 
26) och nedsatt fertilitet (27). 30-50% av kvinnor med endometrios är infertila (3, 11, 28) och av 
infertila kvinnor har 25-40% endometrios (11, 16). 
Diagnosen kan ställas vid titthålsoperation då de typiska härdarna kan ses (9, 10). 
 
Endometrios uppstår enligt rådande hypotes, genom att menstruationsblod med fragment av 
livmoderslemhinna går bakvägen genom äggledarna ut i bukhålan i samband med menstruation. 
Riskfaktorer innefattar riklig eller långvarig mens och missbildningar som försvårar det normala 
avflödet för menstruationen (5, 28, 37-39). Det finns också en stark ärftlig komponent (6, 31, 32). 
Man har hittat förändringar i immunsystemet hos kvinnor med endometrios, vilket kan ha betydelse 
för sjukdomens utveckling och fortskridande (38, 42). Förändringarna kan påverka 
slemhinnefragmentens förmåga att fästa och överleva på bukhinnan (29, 32) och det uppstår en 
kronisk inflammation i bukhålan hos kvinnor med endometrios. Bukvätskan innehåller fler 
immunologiska celler och inflammatoriska substanser jämfört med bukvätskan hos friska (28, 42, 
45). Inflammationen ger upphov till symtom såsom smärta, infertilitet och sammanväxningar (28, 30, 
42). 
 
Det finns ingen permanent bot för endometrios utan tillgängliga behandlingar syftar till att lindra 
symtomen (16). Smärtstillande tabletter och hormonella behandlingar som slår ut mensen (t ex p-
piller) är effektiva liksom kirurgisk behandling då man förstör härdarna och tar bort 
endometrioscystor. Risken är dock stor att besvären återkommer efter att behandlingen avslutats (8, 
9). De hormonella behandlingarna har biverkningar och fungerar som preventivmedel genom at 
hämma ägglossning.  
 
Bakgrund lidokain 
Lidokain är ett lokalbedövningsmedel som först framställdes av den svenske kemisten Nils Löfgren 
1943. Lidokain i höga koncentrationer blockerar nervimpulser och impulser mellan hjärtmuskelceller 
och används som lokalbedövningsmedel och vid hjärtrytmrubbningar (115). De senaste två 
decennierna har man upptäckt att lokalbedövningsmedel i låga koncentrationer har anti-
inflammatoriska egenskaper (115, 118, 122, 133). Om lidokain sköljs genom livmoderhålan och 
genom äggledarna ut i fri bukhåla (pertubation), så ökar chanserna till graviditet (134, 135). Ett 
bifynd vid dessa fertilitetsstudier var minskad mensvärk hos de kvinnor som inte blev gravida (137). 
Höga doser av lidokain kan ge bieffekter (138, 139) och uppstår vid koncentrationer i blod kring 3-5 
µg/ml (116, 138). Nivåer överstigande 20 μg/ml kan orsaka hjärtstopp (138, 140). 
 
Bakgrund livskvalitet 
Hälsorelaterad livskvalitet mäter fysiska, emotionella och sociala aspekter associerade med en viss 
sjukdom eller dess behandling med hjälp av särskilda formulär (145, 146). Ett frågeformulär som 
skall användas vid kliniska studier måste kunna registrera förändringar (149, 150).  EHP-30 
(Endometriosis Health Profile-30) är det enda formulär för endometrios som är validerat och det har 
visat sig vara känsligt för förändring på alla skalor utom en som heter social support eller socialt stöd 
(146, 153, 161).  
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Mål med studierna 
Studierna i denna avhandling syftar till att utvärdera effekten på smärta och livskvalitet hos kvinnor 
med endometrios efter pertubation (genomsköljning) med lidokain. Nivåerna av lidokain i blodet 
efter behandling mättes för att utvärdera metodens säkerhet. Vidare utvärderades om EHP-30 var 
känsligt för förändring i  det aktuella svenska patientmaterialet (150).  
En förklaring till kliniska effekter av lidokain på smärta och fertilitet har studerats på cellnivå.   
 
Metoder 
Studierna har godkänts av Regionala etikprövningsnämnden i Stockholm och av Läkemedelsverket.  
I studie I-IV deltog 42 kvinnor av vilka 24 randomiserades till pertubationsbehandling med lidokain 
och 18 till behandling med placebo. Deltagarna hade menssmärta och endometrios som 
diagnosticerats med titthålsoperation. Tre behandlingar gavs under tre menscykler och 
behandlingseffekten utvärderades med enkäter i upp till ett år efter påbörjad behandling. Enkäterna 
utvärderade smärta och livskvalitet (EHP-30). Blodprover togs före och upp till 30 minuter efter 
behandling för att mäta halterna av lidokain. Med hjälp av svaren på enkäterna utvärderades EHP-30s 
känslighet för förändring.  
I studie V togs vävnadsprov från bukvätska och äggstocks-cystor från 13 kvinnor i samband med 
planerad operation. Kvinnorna hade endometrios eller var friska. Celler från bukvätska och från 
endometrioscystor odlades med eller utan tillsats av lidokain. Produktionen och utsöndringen av tre 
inflammatoriska substanser mättes och jämfördes mellan celler som odlats med eller utan lidokain. 
 
Resultat 
Av de kvinnor som behandlats med lidokain var signifikant fler förbättrade avseende smärtan efter 
sista behandlingen (tio av 24), jämfört med de kvinnor som behandlats med placebo (tre av 18). Hos 
de som förbättrades, kvarstod effekten hos hälften  i upp till nio månader efter tredje behandlingen. 
Drygt två månader efter sista behandlingen hade kvinnorna som behandlats med lidokain en större 
förändring på skalan socialt stöd på EHP-30 jämfört med de som behandlats med placebo (-18.8 
respektive -6.3). Inga skillnader mellan grupperna kunde påvisas efter drygt nio månader. 
Nivåerna av lidokain i blodet efter behandling var mycket låga och den högsta nivån var 0,124 µg/ml 
vilket uppmättes efter 30 minuter. Inga biverkningar beroende på lidokain sågs och behandlingen 
tolererades väl.  
EHP-30 registrerade förändringar på alla skalor i  det aktuella patientmaterialet. De som kände sig 
bättre avseende smärta hade större förändringar på enkäten jämfört med de som var oförändrade eller 
försämrade.  
Cellerna från cystorna som odlades med lidokain hade ett lägre genuttryck och utsöndrade lägre 
halter av den inflammatoriska substansen IL-8 jämfört med cellerna som odlats utan lidokain (4.20 
pg/µg RNA protein med lidokain jfr med 5.95 utan). Tillsats av lidokain hämmade genuttrycket för de 
studerade inflammatoriska substanserna (IL-6, IL-8, MCP-1) i alla cellinjer från bukvätskan hos 
friska kvinnor. Celler från bukvätskan hos kvinnor med endometrios reagerade mer divergerande med 
såväl minskat som ökat genuttryck. 
  
Konklusion 
Pertubationbehandling med lidokain kan minska smärtan och förbättra livskvaliteten hos kvinnor med 
endometrios. Materialet var dock för litet för att säkra slutsatser skall kunna dras. Behandlingen är 
säker och utan biverkningar och mycket låga halter av lidokain kan ses i blodet. Enkäten som 
användes för att utvärdera livskvalitet var känslig för förändring i den studerade patientgruppen, och 
resultaten således pålitliga. Lidokain kan påverka genuttryck och utsöndring av inflammatoriska 
substanser i cellodlingar med celler från endometrioscystor. Celler från bukvätska hos kvinnor med 
endometrios reagerar inte alltid som celler från friska kvinnor. Detta kan vara en del i förklaringen till 
att inte alla kvinnor förbättrades av pertubationsbehandlingen. Ytterligare studier behövs för att 
bekräfta effekten av lidokain på smärta och livskvalitet vid endometrios.  Studien av koncentrationen 
i blodet, visar att man utan risk kan öka lidokaindosen något för att om möjligt förbättra effekten. 
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